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7Introduction
This is the first of the three annual work programmes 
required to implement the activities and commitments 
set out in the EMCDDA’s new strategy for the 
2013–15 period (1). It is based on the fact that the 
agency needs not only to take forward those tasks 
necessary for the ongoing monitoring and reporting 
on the European drug situation, but also to pave the 
way for the new developments and performance 
improvements that we have committed ourselves to 
over this period.
The central challenge for the EMCDDA is to continue 
to deliver high-quality analyses on established 
topics at the same time as extending its work in 
less developed but strategically important areas. As 
the European drug problem evolves, the EMCDDA 
must also ensure that its tools and approaches keep 
pace with developments and remain fit for purpose. 
Moreover, information needs are changing greatly 
and to remain relevant and useful we must ensure 
our outputs are in a format that meets contemporary 
and future expectations.
This work programme is framed around the need 
to ensure continuity and protect core business 
while preparing for strategic changes and scaling 
up activities in some areas. This needs to be 
accomplished within static or contracting resources. 
In simple terms, over the next three years we 
must deliver more with the same resources. This 
can be achieved only by setting clear priorities, 
ensuring that all activities give maximum value, 
pursuing synergies, working efficiently and reducing 
investment in less productive areas. In order to 
ensure appropriate prioritisation of activities, the 
2013 work programme has been informed by a 
comprehensive priority setting exercise conducted 
during the planning and preparatory phases, in 
line with the priorities defined in the 2013-15 
(1) EMCDDA strategy and work programme 2013–15 is available at: www.emcdda.europa.eu/publications/work-programmes/2013-15
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EMCDDA strategy and work programme and 
taking into consideration the anticipated policy 
developments at the EU level (Drug Strategy 2013 
– 2020 and Action Plans, and new legislation on 
new psychoactive substances). Furthermore, during 
the implementation of the work programme we 
will review our planning, as necessary, in order to 
allow reassignment of resources from less productive 
areas towards the critically important ones. 
Investments made in previous years in developing 
the EMCDDA’s internal management, planning and 
assessment capacity mean the agency is better 
placed to make these efficiency gains. It is also 
important to note that progress in developing new 
areas will depend on resource availability and, 
equally importantly, the willingness and capacity of 
Member States to support national data collection 
activities. The EMCDDA’s achievements are a shared 
accomplishment. We rely on the data that are 
collected by the Member States and subsequently 
analysed and transmitted to us by the Reitox network 
of national focal points. In this context, it must be 
acknowledged that the current situation in many 
parts of Europe is difficult. In summary: this annual 
work programme remains ambitious in its outlook 
but is necessarily informed by the need to adopt a 
realistic, pragmatic and developmental approach 
which is sensitive to the current challenges, both at 
the European level and within our Member States, of 
data collection and reporting capacities.
The resources required for implementing the 2013 
work programme will be provided by the EMCDDA 
budget for 2013, as adopted by its Management 
Board, on the basis of the decision of the Budgetary 
Authority on the European Commission (EC) annual 
subsidy to the EMCDDA’s budget. The EC annual 
subsidy on which the 2013 EMCDDA budget relies 
is expected to amount to EUR 15 550 000. This 
work programme has been drawn up on the basis of 
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this estimate. Changes in the amount would require 
us to adjust the activities proposed here.
2013: a strategically important year for 
reporting on drug use in Europe
The year 2013 is important for ensuring that the 
agency’s work meets EU-level information needs. 
The EMCDDA’s work is governed by its recast 
Regulation (2), but, within this context, activities 
are always made as relevant as possible to policy 
developments. The agency is recognised as an 
important information provider to support the 
information needs arising from EU-level coordination 
and cooperation activities. During 2012, the EU 
has been working on a new drugs strategy, and a 
new implementation plan is envisaged in 2013. 
The implications of the new plan for the work of the 
EMCDDA will become fully clear only when it is 
finalised. We expect, however, that current activities 
will need to be reviewed and adjusted to ensure 
work is in line with the needs of the new EU strategy. 
This requirement has been taken into consideration 
in this work programme.
The drugs strategy is not the only ongoing policy 
discussion that is likely to affect the work of the 
EMCDDA in 2013. Over the last few years, across 
Europe the sale of new uncontrolled psychoactive 
substances as replacement products for controlled 
drugs has become an issue of growing policy 
interest and concern. The Council Decision on new 
psychoactive substances provides the legal basis for 
the work conducted by the EMCDDA and Europol 
to implement the European early warning system, 
and this mechanism is currently under review. The 
European Commission assessed the mechanism in 
2011, and discussions on its future development 
have continued during 2012. We expect a new 
legislative proposal to be put forward that will 
require adjustments to the agency’s work in this area 
during 2013. We remain in close communication 
with the Commission on this issue. It is also important 
to note here that the obligations of the EMCDDA 
in respect to the current mechanisms appear to 
be growing. For planning purposes we can only 
(2) www.emcdda.europa.eu/html.cfm/index24213EN.html
anticipate what will be required in 2013. Should 
additional activities be necessary, either because a 
greater volume of substances is reported or because 
we need to conduct additional formal activities, 
such as risk assessment exercises, the current work 
programme will need to be reviewed. Should this 
be necessary, it could impact on other planned 
activities.
The EMCDDA was founded on the precept that 
a better understanding of the drug situation, in 
all its aspects, is needed for the development of 
effective policies and actions. The unique value 
of the analysis provided by the agency is that it 
brings together information from multiple sources 
and perspectives. Crucially, we offer an analysis 
that unites both demand- and supply-side data. We 
recognise, however, that supply-side data sources 
remain poorly developed at the European level. This 
limits our capacity to make comparative analyses 
and monitor important changes in drug availability 
and the functioning of the drug market over time. The 
EMCDDA has been working in close collaboration 
with the Commission and Europol to develop a 
proposal for European key indicators on drug supply 
and a roadmap for their implementation. This work 
will conclude in 2012 and follow-up activities are 
included in the 2013 work programme. We have 
planned activities within existing resources and 
with the expectation that the key indicator technical 
proposal will be endorsed. As supply reduction data 
remain an important topic on the policy agenda, 
and as discussions on the technical proposal and 
information needs in general will continue during 
2013, the agency will monitor developments and 
review the work planned if necessary.
Highlights of the 2013 work programme
Three core principles drive progress and guide 
change in the three-year work programme. They are 
a commitment to providing a relevant, timely and 
responsive analysis of the drug situation; achieving 
efficiency and ensuring that maximum value is 
delivered from activities and investments; and 
enhancing communication and a customer-orientated 
approach. These overarching principles shape and 
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focus our activities and are reflected in each of the 
substantive areas described below. 
An exciting development in 2013 is that the 
EMCDDA will completely rethink the Annual report, 
one of its flagship products. Instead of producing 
it as a printed document, we will replace it with an 
integrated and comprehensive set of linked reporting 
products. These will reflect modern information needs 
and provide multiple entry points into the wealth 
of information and analysis available from the 
EMCDDA We will do this in stages to implement the 
improvements envisaged in the new communication 
strategy and three-year work programme.
The new Annual report package will exploit the 
benefits of online publishing. Reporting will be more 
timely and efficient, with a shorter, more strategic, 
summary report released in the first half of the year, 
accompanied by, and linked to, a more interactive 
detailed statistical bulletin. Additional elements will 
include a number of short interactive ‘spotlights’, 
highlighting important new analysis, findings and 
recent developments. These will increase the shelf 
life and value of the product, as they will grow over 
time to form an online archive and link to EMCDDA 
analysis and reports. There will also be a policy 
summary and press notes. These windows into the 
work of the EMCDDA will be designed to allow users 
to navigate easily to the information they require and 
access it in a form appropriate for their own needs. 
A priority for 2013 will be to redesign and improve 
the EMCDDA’s web presence; the goal will be to 
launch the new web concept in 2014.
A commitment to quality runs through the new three-
year strategy and work programme. Several quality 
assurance projects will address both substantive 
and process issues. Reflecting the importance of 
quality assurance, the EMCDDA will establish a 
new cross-unit project (CUP) to coordinate and 
oversee activities and monitor progress. Examples 
planned for 2013 include developing a new quality 
assurance framework for statistics; auditing key 
indicator implementation; improving the value of 
technical meetings; and grading information. We 
also intend to improve data submission processes. 
As some of these issues directly concern the focal 
points, and many important activities planned 
with the Reitox network in 2013 involve quality 
assurance, we are setting up a joint working group. 
These activities include following up the systemic 
review, revisiting and updating reporting tools and 
developing a model for focal point accreditation. 
We will also train and support members of Reitox in 
reporting to the EMCDDA and increasing the value 
and visibility of focal points at national level.
CUPs provide a flexible mechanism for driving 
complex activities that require working across units. 
The treatment CUP will be continued in 2013 but 
with a new objective of implementing the new 
treatment strategy and encouraging analysis on 
this topic across the scientific teams. New CUPs 
will also be launched to coordinate activities in 
two other areas. A CUP on trendspotting will bring 
together the different staff working on this issue 
across the EMCDDA, and help improve analysis 
and information sharing. In 2013 two trendspotting 
meetings are planned; the first of these will focus on 
changes in use and availability of methamphetamine. 
Also the CUP on misuse of medicines will initiate its 
work in 2013. The work of the CUP will be in full 
accordance with the EMCDDA mandate and support 
collaboration with the European Medicines Agency 
(EMA).
The new three-year strategy includes a small number 
of important major new scientific publications. These 
projects are planned for over the course of the three-
year work programme, and 2013 will see the launch 
of the work necessary for major new reports on 
drug policy, the state of the art in drug prevention, 
drug overdose and hepatitis C. Among the products 
planned for release in 2013 are a new review of the 
treatment of cannabis-related disorders, an overview 
on therapeutic communities and an update to the 
existing insights on the evidence base about drugs 
and driving. A major new joint report with Europol 
will also be launched early in 2013, which will 
provide a strategic analysis of the European drug 
market. This document will bring together and add 
value to the information and knowledge held by both 
organisations and is intended to support discourse 
and policy formation on this important topic. A full 
list of major outputs can be found in the list of outputs 
presented below.
In the area of monitoring the drug situation, the new 
annual work programme sees a shift in emphasis 
towards analytical tasks for the EMCDDA’s scientific 
teams. Transversal analysis, which brings together 
response and epidemiological data, will be given 
special emphasis, as will projects on the complex 
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issue of polydrug consumption. Some important 
developmental or methodological work will still 
be necessary, however; examples include work to 
improve the mapping of treatment availability, review 
the data collection strategy in the area of infectious 
diseases and develop options for better monitoring of 
drug-related emergencies. In the new drugs area the 
current database will be improved and the Internet 
monitoring strategy refined. The best practice portal 
will also be redesigned, in the context of our overall 
web development strategy, and with the aim of 
increasing the online dissemination of information 
relevant to improving practice. Developmental work 
will also concentrate on developing information 
sources and improving analysis in the area of 
supply reduction. We plan a number of important 
new studies for 2013; they are listed in Section II 
below. Among these are a new review of the typical 
penalties received for drug-trafficking offences and a 
new analysis of drug-injecting trends.
The ability to produce high-quality scientific outputs 
depends on an efficient and well-functioning 
administrative and technical infrastructure. The 
EMCDDA has been actively developing its internal 
systems for planning, monitoring, risk assessment 
and quality assurance. This work will continue in 
2013. As in all EU agencies, we continually need 
to ensure that the agency’s administrative processes 
reflect current EU regulations and recognised good 
practices. We do this proactively and are committed 
to remaining a leader in ensuring good governance. 
Moreover, technical and administrative tasks rely 
on fully functional internal information technology 
systems. Ensuring high-quality services in this area 
can be challenging for decentralised agencies, so 
the EMCDDA is particularly fortunate in its strong 
information technology support team. The team 
works closely with technical and administrative 
staff to ensure that it understands our information 
technology needs and provides appropriate 
solutions. In 2013, along with ongoing improvements 
and developments to the infrastructure, the team will 
work on improving web-based resources, to support 
the web changes discussed above.
Partnership and added value
The EMCDDA’s results are possible only through 
partnership with national data providers and experts 
as well as with relevant EU bodies and international 
organisations. The Reitox network of national 
focal points (NFPs) provides most of the data for 
the agency’s outputs, and our success depends 
on strong collaboration with them. The Reitox 
network is a unique feature of the European drug 
information system. It not only allows comparable 
data to be collected in all Member States but 
also provides feedback and helps ensure that the 
agency’s analyses are grounded in an understanding 
of the unique national situations across the EU. 
The work of the NFPs is supported by a variety 
of expert networks, working both nationally and 
with the EMCDDA. Important examples of these 
include the key indicator working groups, the legal 
correspondents’ network, the European school survey 
project on alcohol and other drugs (ESPAD) and the 
early warning system network. The Cochrane Group 
on Drugs and Alcohol and the European Society for 
Prevention Research are important contributors on 
the responses side. In 2013, it will be necessary to 
develop a network in the forensic science area and a 
reference group on supply reduction data. 
The EMCDDA recognises the benefits and efficiency 
that come through joint work with other institutional 
partners. Added value at the EU level comes from 
joined-up working practices, and products can 
have additional authority and value when they are 
endorsed by the key institutions working in the area. 
In 2013, the EMCDDA will continue to prioritise 
working in partnership for operational analysis and 
to establish guidelines and standards with other 
relevant European agencies. We should mention in 
particular the joint analyses and information-sharing 
activities conducted with Europol, the European 
Centre for Disease Prevention and Control (ECDC) 
and the EMA. The drugs problem is ever more 
connected around the world, and the EMCDDA 
can provide European technical expertise and 
experience, so we will continue cooperating as 
appropriate with the international agencies working 
on drug issues, most importantly, but not limited 
to, the United Nations Office on Drugs and Crime 
(UNODC) and the World Health Organisation 
(WHO). We will also pursue technical and 
scientific partnerships. The EMCDDA has areas of 
common interest and collaborates with a number of 
national centres of excellence in drug monitoring 
and research, both within the EU and worldwide. 
In addition, we are looking for synergy and 
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appropriate collaboration with various European 
research initiatives.
Structure of the work programme
This work programme has been developed from a 
detailed planning exercise completed by each of 
the agency’s units. The exercise has been informed 
by the requirements of the new three-year work 
programme and strategy (2013–15) and guided 
by the agency’s recast Regulation. For each area, 
highlights of the work in 2013 are presented 
in the Overviews. In order to ensure coherence 
and allow proper monitoring of achievements 
over the next three years, specific objectives and 
priority interventions are defined for each of the 
main areas of work, mirroring the structure of the 
2013–15 strategy and work programme. Priority 
interventions are accompanied by their related 
activities and expected outputs or results, which will 
help achieve the key expected results defined in the 
work programme. This structure reflects the ongoing 
rationalisation of planning processes and procedures 
taking place within the EMCDDA. It should be 
noted that some outcomes, especially those related 
to specific analyses, are indicative as they depend 
on the results of preliminary interrogation of 
data. Activities under the risk assessment of new 
psychoactive substances depend on actual need. For 
the reasons noted above, and because the EMCDDA 
has to respond to important ad hoc information 
requests and new developments, some flexibility is 
built into the planning process, along with regular 
reviews to ensure that we are using resources to the 
best advantage and meeting important information 
needs as they emerge.
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Key outputs to be published in 2013 and their intended audience
Output Policy Other target audiences
Science Practice Citizen
Annual reporting
Annual report package: strategic summary report (printed, 22 
‘EMCDDA’ languages, plus 5 languages covering candidate and 
potential candidate countries), interactive statistical bulletin and topic-
based ‘spotlights’, country overviews, policy summary and press notes
x x x x
Technical publications
EMCDDA Monographs
•	 New groups of psychoactive substances in Europe
(printed, PDF, EN)
x x
EMCDDA Insights
•	 Treatment of cannabis-related disorders
•	 Drugs and driving
•	 Therapeutic communities
(printed, PDF, EN)
x x x
EMCDDA Manuals (Guidelines, standards and protocols)
Technical guidelines:
•	 Cannabis disorders estimation in general population surveys (GPS)
•	 Revised problem drug use (PDU)
•	 DRID Toolkit (3 modules)
•	 Online surveys
•	 Internet monitoring
(online, PDF, EN)
x x
EMCDDA Papers
Policy papers on: 
•	 Ireland
•	 Drug policies of large cities
•	 Trends in drug-related expenditure
•	 Alternatives to punishment
•	 Drug policy advocacy groups
Technical papers on: 
•	 Environmental prevention
•	 Residential care in Europe
•	 Polydrug use in school and adult population
•	 Mortality cohorts studies among drug users
•	 Stimulant use and HIV risks in injectors and non-injectors
•	 Injection trends
•	 Interpolation of trends
(online, PDF, EN)
x x x
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Output Policy Other target audiences
Science Practice Citizen
EMCDDA Online
Ongoing development and content updating of the EMCDDA’s public 
website. This includes regular and cyclical content updating including:
•	 Statistical bulletin
•	 Country overviews and other country data
•	 Best practice portal (including EIB and EDDRA)
•	 The European database on new drugs (EDND) (online, restricted)
•	 News and events
•	 Topical content areas (policy and law, health and social 
interventions, indicator resources pages, research, drug profiles, 
etc.)
New content:
•	 New drug profiles (if appropriate)
•	 Data spotlights
•	 New topic areas
(online, EN, with some multilingual sections)
   x x x x
EMCDDA Reports (institutional and implementation reports and joint publications)
•	 Joint EMCDDA–Europol publication — the EU report on drug 
markets: a strategic analysis (printed, EN)
•	 ESPAD summary in Albanian and Croatian (PDF)
•	 General report of activities 2012 (printed, EN)
•	 EMCDDA 2013 work programme (online, PDF, EN)
Outputs related to the implementation of the Council Decision 
2005/387/JHA:
•	 EMCDDA–Europol report on the implementation of the Decision 
(Article 10 report)
•	 EMCDDA–Europol joint report and risk assessment (if necessary)
(online, PDF, EN)
x
x
x
x
x
x
x
x
x
x
x
x
x
x
EMCDDA Updates
•	 Trendspotter case study
(PDF, EN)
x x x
Drugnet Europe newsletter (printed and online, EN, four issues) x x x x
14
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II.1. Data collection, analysis and 
quality assurance
Overview
The fundamental data collection tasks remain 
essential to the EMCDDA’s mission. The purpose 
of the data collection is the aggregation and 
manipulation of data into tables, graphs and 
appropriate analyses for a range of both internal 
and external stakeholders. Internally the data are 
used to support reasoned descriptions of the drug 
situation in Europe, presented through the EMCDDA’s 
Annual report and other publications. Externally, 
policymakers, researchers, the European civil service 
and the European public have access to reliable and 
valid data on the drug situation in each of the 27 
Member States, Norway, Croatia and Turkey through 
the EMCDDA’s publications and the online Statistical 
bulletin. The fundamental tasks of data collection and 
analyses will continue in 2013; however, they will 
be influenced by some important new developments.
The revised format of the Annual report and the 
subsequent emphasis on web-based products, the 
proposed changes to the Statistical bulletin and the 
movement towards a statistical quality framework are 
the main pillars of work for this area in 2013.
The new Annual report format will influence the 
data collection and analysis in 2013, and the data 
production process will be adapted to meet the 
demands of an earlier publication date and of the 
new concept of the EMCDDA flagship product. The 
shortened production schedule will require more 
rapid turnover of validations, and the new format 
will require new types of analyses, with an emphasis 
on incorporating information from more than one 
indicator.
The changed timeline for the Annual report will also 
have an impact on the web-based data collection 
II. Main areas of work in 2013
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system Fonte and related processes. This will involve 
a revision of deadlines for the production of Fonte 
templates, from 1 February to 1 March, which has 
been agreed in consultation with the data providers, 
the NFPs. In addition, to allow earlier submission of 
data, and at the request of the NFPs, the opening 
date of Fonte for 2013 will be brought forward two 
months, to 2 March. Furthermore, Fonte software 
will be developed to allow data providers to view a 
summary of the reports they have submitted, along 
with each report’s status.
Broader changes to data collection instruments will 
occur in the longer term within the framework of 
the systemic review of tools. In 2013, the revision 
work will include the data collection tools for the 
Treatment demand indicator (TDI), the voluntary 
behavioural data section of Drug-related infectious 
diseases (DRID), survey results from targeted 
groups and Problem drug use (PDU). Results of 
the pilot of the new TDI template will be analysed 
and any necessary changes made. The structured 
questionnaire 32 on drug policies will also undergo 
a small revision process in order to be adopted by 
the national focal points in late 2013 for a data 
collection exercise to be implemented in 2014.
Based on the new treatment and prison data 
collection strategies, instruments and data collection 
procedures will be revised, taking into account the 
changes necessary for the production of the new 
Annual report.
One of the main components of the Annual report 
package is the Statistical bulletin. Following the 
new concept for the Annual report, plans for a 
change in the structure of the Statistical bulletin will 
be developed during 2013, with implementation 
envisaged in 2014. The current Statistical bulletin 
contains both reported data and analyses. A 
structure will be sought to complement the emphasis 
on web products, to improve the documentation 
of analyses and to better serve the users of the 
product. Moreover, as the user-friendliness of the 
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online product has improved over the past few years, 
further efforts will be made to continue this trend in 
2013.
Within the systemic review, overall issues of quality 
assurance of data have been considered, and an 
organising committee is to be established to oversee 
work in this area. Throughout, by the very nature of 
the available data on the drug situation, a balance 
has to be reached between statistical probity and 
the need for information through clear and visible 
documentation. As part of the data quality assurance 
process, cross-indicator tables, integrating data from 
different data sets, will be developed to help better 
validate and analyse data which come, for example, 
from epidemiology, health and social interventions, 
prevention, supply reduction and policy.
Furthermore, the format of the quality reports will 
be reviewed in 2013. Consolidation of quality and 
processes for data collection through the Reitox 
network will also include participation in internal 
working groups, as well as capacity development 
activities organised by the Reitox Academy.
The adoption of a statistical quality framework is 
anticipated over the 2013–15 period. In the first 
year, a suitable set of guiding principles, a plan 
for the implementation and some initial structures 
will be developed. Given that the EMCDDA is 
an EU agency, it will probably adopt a set of 
principles deriving from the European Statistics 
Code of Practice from Eurostat, or the appropriate 
components of it. Furthermore, existing practices 
will be reviewed in 2013 with support from an 
external contractor, with particular reference to 
documentation, grading of data and appropriateness 
of estimation.
Quantitative, full coverage information is often not 
available in Member States. Therefore, especially 
for the monitoring of interventions, expert ratings are 
used frequently. A study will help to further develop 
these instruments and the collection of qualitative 
data through structured questionnaires in general. 
The results of the study will inform future revisions of 
data collection tools and processes and will help to 
apply them in a more systematic way in all areas of 
data collection.
Goal 2013–15: A coherent, reliable and valid data collection system, underpinned by a quality assurance 
framework
Specific objective 1.1: Improve data collection instruments and processes
Priority interventions Planned activities Expected outputs/results
1.1.1. Revise the reporting system to 
improve coherence and efficiency
1.1.1.1. Launch the revision process 
of the national reporting package with 
NFPs
•	 Work plan for 2013 revision 
adopted at May NFP meeting and 
implemented
1.1.2. Implement new data collection 
exercises, based on revised tools
1.1.2.1. Implement the new data 
collection cycle, starting from 2013
•	 Revised data collection tools 
(standard tables/structured 
questionnaires) conceptualised
1.1.2.2. Revise data collection tools in 
consultation with NFPs
•	 New TDI template
•	 New standard table for reporting 
on surveys of targeted groups
•	 New standard template 9 (ST9) 
part III
•	 New PDU template
•	 New structured questionnaire on 
drug policies
1.1.2.3. Revise treatment data 
collection tools in line with the new 
treatment data collection and analysis 
strategy
•	 Treatment data collection tools 
revised and adapted
1.1.2.4. Revise prison data collection 
tools in line with the new prison data 
collection and analysis strategy
•	 Prison data collection instruments 
reviewed
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Priority interventions Planned activities Expected outputs/results
1.1.2.5. Assist NFP for automatic 
submission of TDI to Fonte
•	 Five additional NFPs provided with 
support to submit their TDI Fonte 
templates automatically
1.1.3. Maintain and further develop 
(as required) the Fonte reporting 
system and data warehouse
1.1.3.1. Maintain and develop the 
Fonte system
•	 Systems for drug data collection 
operational
•	 Software to include a summary 
of reports and their status by 
country developed, in line with 
NFP requests (based on available 
resources)
1.1.3.2. Adapt existing work 
processes to reflect reporting needs
•	 Work processes aligned to the new 
Annual report production cycle
Specific objective 1.2: Strengthen and develop the quality assurance framework to support data collection, 
statistical analysis and data reporting
Priority interventions Planned activities Expected outputs/results
1.2.1. Develop a cross-indicator 
approach to improve data validation 
and analysis
1.2.1.1. Construct thematic data 
tables to improve data validation and 
analysis
•	  Thematic data tables available for 
analysis and coherence checking
1.2.2. Review, rationalise and develop 
existing quality assurance measures 
around data collection
1.2.2.1. Implement cross-checking of 
data between the National reports 
and the Statistical bulletin tables for a 
selected number of indicators
•	 Improved validity and reliability of 
the data received
1.2.2.2. Carry out checks of EMCDDA 
data with data from external sources
•	 Data checks with external sources, 
in particular ECDC/WHO 
1.2.2.3. Monitor the quality of the 
data reported by the NFPs and 
provide feedback and support to 
improve the reporting
•	 30 quality reports prepared and 
delivered to NFPs in May 
1.2.2.4. Review the format of the 
quality reports
•	 Proposal for a new quality reports 
format developed and adopted at 
the Heads of national focal points 
meeting in November
1.2.3. Develop a statistical quality 
framework for the analysis, 
manipulation and reporting of data 
within the EMCDDA
1.2.3.1. Develop set of principles to 
be adopted as part of the statistical 
quality framework
•	  Set of principles for a statistical 
quality framework developed and 
endorsed internally
1.2.3.2. Review the documentation 
of results, the grading of data, and 
appropriateness of estimations (based 
on work started in 2012)
•	  Improved documentation; proposals 
for grading of data; improved 
methodology for estimations
1.2.3.3. Produce the 2013 Statistical 
bulletin and review the structure of the 
product to complement the new Annual 
report concept and the increased 
emphasis on web products
•	  2013 Statistical bulletin published 
online
•	  Proposal for the new Statistical 
bulletin developed and endorsed 
internally (to be implemented from 
2014)
1.2.3.4. Conduct study to improve 
semi-structured qualitative information 
obtained through expert ratings 
•	  Project report prepared, including 
recommendations and draft 
protocols
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II.2. Monitoring and understanding 
drug use and problems: key indicators 
and epidemiology
The epidemiological monitoring of drug use 
prevalence and patterns, as well as health and social 
consequences, is at the heart of the EMCDDA’s 
work. It aims to facilitate a reliable diagnosis of 
the drug situation, which in turn is the basis for 
developing solutions and evaluating whether or not 
they work. Epidemiological indicators provide the 
long-term, standardised time series analysis that is an 
important part of the added value provided by the 
European monitoring system. We have developed 
standard methodologies to allow Member States 
to collect information in an increasingly sound and 
comparable way.
Our goal by the end of 2015 is to provide a further 
improved and insightful overview of the European 
drug situation, by enhancing analysis of the 
epidemiological information and key indicators. As 
2013 is the first year within the 2013–15 strategy 
and work programme, it is an important year for 
both planning and substantive activities.
With the European drug problem constantly evolving, 
it is important that we ensure progress in the 
methodological development of the epidemiological 
key indicators and that our epidemiological 
approaches keep pace and remain fit for purpose. 
Among the new developments planned for 2013 are 
activities to explore how data on acute drug-related 
emergencies can be collected. In the area of general 
population surveys, we have planned to explore the 
use of computer-based and online methods and to 
evaluate the costs and benefits of these survey tools.
Adolescents are a key population regarding initiation 
and prevention of drug use and drug problems. The 
collaboration with the ESPAD schools project will be 
strengthened in 2013. Following a recent agreement 
to scale up cooperation, the EMCDDA will increase 
its support for ESPAD activities during the course of 
this work programme.
Reflecting the move towards increased online 
dissemination of information in all domains, the 
web-based epidemiological information will 
be rationalised and improved. This will require 
reviewing existing resources for reporting summary 
and national data, methodological information and 
analysis.
Health and drugs monitoring is necessarily a 
long-term and systematic endeavour. In 2013, the 
EMCDDA will continue its ongoing activities to assist 
the NFPs in the implementation of the key indicators. 
Once implementation needs have been identified, 
support programmes including training activities and 
on-site assistance will be developed.
At the same time, monitoring should be both 
followed up with and driven by analysis and 
understanding of the results of data collection. In 
this work programme we stress and reinforce the 
analytical activities, as a natural development after 
the long-term methodological work. We will improve 
the current expert meeting format to give more 
opportunity for discussion and analysis. As part of 
the commitments to quality assurance and efficiency, 
we will hold some expert meetings back-to-back 
to allow crossover sessions at which experts from 
different disciplines can work together. At the same 
time, as part of the commitment to timeliness, we will 
better capture the findings from the expert meetings 
and make them available more rapidly.
To reflect the objective of placing emphasis on 
analysis, we will also improve the exploitation of our 
data through cross-indicator analysis and validation. 
Efforts will be focused on moving from an individual 
indicator perspective to a multi-indicator one.
Polydrug use is now common across the EU and 
this has important implications for both the harms 
associated with different consumption patterns 
and the design of responses. Key indicator data 
from GPS, TDI and DRD (drug-related deaths) will 
be analysed in order to provide insights into the 
prevalence and patterns of polydrug use in the EU.
In addition, the analysis of key indicator data is 
an important contribution to rapid assessment 
(‘trendspotting’) activities. We will work to strengthen 
the integration of key indicator data with other data 
sources in order to ensure that the monitoring system 
remains relevant to European needs. An increased 
number of rapid data collection exercises may be 
needed in order to analyse emerging trends in the 
European drug situation or to address potential 
outbreaks of drug-related diseases or unusual clusters 
of drug-related deaths.
Another line of work for 2013 in this area is to 
promote harmonisation of national analysis to act 
as a catalyst for later multi-country analysis by the 
EMCDDA and the countries themselves. In 2013, 
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we will draft guidelines for the Member States to 
promote harmonised analysis of some key indicators 
at national level.
One of the main purposes of understanding patterns 
of drug use and their consequences is to facilitate 
the design and evaluation of interventions. To reflect 
this objective, many of the analysis we will undertake 
in 2013 integrate epidemiological and response 
indicators. The key indicators provide the empirical 
building blocks on which many of these complex 
analyses depend. One example of the integration 
of the epidemiological and response indicators 
can be found in the activity that will analyse the 
difference between out-of-treatment and in-treatment 
populations.
Goal 2013–15: Provide an integrated and insightful overview of the European drug situation by enhancing 
analysis of the epidemiological key indicators, including cross-indicator analysis and combined analysis with 
other sources of information, while ensuring the quality of the information collected by Member States and 
the EMCDDA
Specific objective 2.1: Ensure progress in the methodological development of the epidemiological key 
indicators (KIs)
Priority interventions Planned activities Expected outputs/results
2.1.1. Maintain and further 
develop methodological tools for KI 
implementation
2.1.1.1. Develop guidelines for 
conducting and interpreting online 
surveys in GPS 
•	 Final project report
•	  Guidelines for online surveys 
published online
2.1.1.2. Map ‘new drug’ questions 
used in GPS 
•	  New European Model 
Questionnaire (EMQ) module on 
‘new drugs’ developed
•	  Expert meeting organised
2.1.1.3. Carry out work on cannabis 
disorders estimation guidelines
•	  Guidelines on how to use scales in 
GPS published online
•	  Expert meeting organised
2.1.1.4. Finalise new indirect PDU 
guidelines
•	  Guidelines published online
2.1.1.5. Explore feasibility of using 
hospital emergencies as information 
source on health consequences
•	  Internal strategy prepared
2.1.1.6. Finalise DRID toolkit •	  Three modules published online
2.1.1.7. Conduct strategic review of 
progress in the area of DRID 
•	  Internal strategy for collecting 
information on infectious diseases 
related to drug use developed  
2.1.1.8. Revise guidelines for data 
collection on treatment prevalence 
based on TDI data collection 
•	 TDI prevalence module revised and 
improved
•	  Expert meeting organised
2.1.2. Cooperate on methods and 
exchange information with other EU 
and international institutions (within 
mandate and where appropriate)
2.1.2.1. Collaborate with external 
partners and projects (see also 
objectives 8.1, 8.2 and 8.3)
•	  Improved collaboration and joint 
activities implemented 
2.1.3. Scale up cooperation with 
ESPAD project
2.1.3.1. Develop joint work 
programme
•	  Joint EMCDDA–ESPAD work 
programme
•	  Analysis plan prepared to initiate 
work on ESPAD database
2.1.4. Rationalise and improve 
web-based information on the drug 
situation
2.1.4.1. Update and develop the 
website information (public and 
restricted area)
•	  Integrated KI overviews
•	  Increased quality and accessibility 
of online information on KIs (drug- 
and country-specific overviews) 
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Specific objective 2.2: Support the implementation of the key indicators by the Member States, through ongoing 
monitoring and provision of technical guidance and training
Priority interventions Planned activities Expected outputs/results
2.2.1. Actively monitor implementation 
of KIs and identify implementation 
needs
2.2.1.1. Monitor the status of 
implementation of the five KIs (GPS, 
TDI, DRD, DRID, PDU) for each country 
•	  Annual interim reports developed 
for all the five key indicators and 
follow-up implemented as needed
2.2.2. Provide expert advice and 
training to support the countries, as 
needed 
2.2.2.1. Provide scientific and 
technical advice and support to 
national experts and the NFPs
•	  Training programmes developed 
and delivered as required, based 
on identified needs  
2.2.3. Support key indicator 
implementation
2.2.3.1. Support countries in 
implementation of key epidemiological 
indicators 
•	  Countries assisted as needed in the 
implementation of all key indicators 
(based on availability of resources)
•	  Support for the implementation of 
new mortality cohorts, reporting 
of data from cohort studies and 
improved general mortality registers 
and special registers
•	  TDI version 3.0 implemented at 
national level 
2.2.4. Support the implementation of 
KIs in third countries and international 
efforts to improve reporting capacity 
(see objectives 8.4.1 and 8.4.2 for 
details)
2.2.4.1. Provide training and support 
(where appropriate and based on 
available resources)
•	  Training and advice activities 
conducted, materials produced and 
implementation supported
Specific objective 2.3: Maximise the value of key indicator information through analysis to provide a 
comprehensive, relevant and multi-source understanding of contemporary patterns of drug use, trends and 
related health and social consequences
Priority interventions Planned activities Expected outputs/results
2.3.1. Organise European key 
indicator expert meetings 
2.3.1.1. Organise the annual 
European expert meeting/conference 
for each key indicator (GPS, TDI, 
DRID, DRD, PDU)  
•	  Annual European expert meetings 
organised for all five key indicators; 
documents, presentations, results 
available online and on the 
dedicated experts’ extranet areas
•	  New expert meeting concept 
developed
•	  Improved methodological and 
analytical capacity of the EMCDDA 
and Member States
2.3.2. Improve exploitation of data 
through standalone and cross-indicator 
analysis
2.3.2.1. Prepare structured analysis 
plans to support the annual reporting 
packages analyses and other outputs
•	  Internal working document
2.3.2.2. Prepare focused analyses for 
improved online dissemination of key 
indicators data
•	 Minimum of one focused analysis 
per indicator area published online 
(indicative topics: polydrug use and 
age; trends in treatment uptake; 
trends in PDU; new developments in 
estimating indirect drug deaths)
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Priority interventions Planned activities Expected outputs/results
2.3.2.3. Conduct advanced analysis 
of polydrug data
•	  Technical paper on polydrug use 
in school and adult population 
published online (based on ESPAD 
and GPS data)
2.3.2.4. Finalise project to explore 
possible interpolation of trends based 
on routine data (PDU)
•	  Technical paper published online
2.3.2.5. Organise data analysis 
workshop (data lab) to analyse and 
report new mortality cohorts and 
conduct multi-country pooled analysis
•	  Data lab organised
•	 Technical paper published online
2.3.2.6. Finalise project on stimulant 
use and HIV risks in injectors and non-
injectors
•	 Technical paper published online
2.3.3 Develop guidelines for and 
promote analysis at national level
2.3.3.1. Develop and implement 
standard analysis plans to support 
NFPs to improve reporting and 
analysis at national level 
•	  Standard models for analysis 
plans developed for the KIs and 
implemented during annual expert 
meetings
2.3.3.2. Consolidate and expand 
European Surveys Harmonised 
Database project (adding at least two 
more countries)
•	  Decentralised European database 
to support cross-country analysis
2.3.4. Develop complex cross-
epidemiological indicator analysis and 
analysis integrating epidemiological 
and response indicators
2.3.4.1. Conduct multi-indicator 
analysis on differences between out-of-
treatment and in-treatment populations
•	  Project report prepared on the 
analytical potential of out-of 
treatment population studies
•	  Expert meeting 
2.3.4.2. Conduct multi-indicator HIV 
outbreak assessment (if requested, e.g. 
from Romania)
•	  Technical report prepared
2.3.4.3. Finalise integration of TDI 
prevalence module in the treatment 
system-based data collection and 
analysis strategy
•	  TDI prevalence module integrated 
in the treatment system-based data 
collection and analysis strategy
2.3.4.4. Finalise analysis to estimate 
prevalence of drug injection based on 
TDI and PDU data
•	  Final report /technical paper on 
injection trend (PDU–TDI) published 
online
2.3.4.5. Prepare in-depth topical 
review on psychiatric co-morbidities 
(EMCDDA Insights series)
•	  First draft prepared (publication in 
2014)
2.3.4.6. Disseminate key results •	  Presentations delivered at scientific 
events and conferences
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II.3. Monitoring demand reduction 
responses applied to drug-related 
problems
Overview
Describing the demand reduction measures that 
Member States take to address drug problems is a 
core aspect of the EMCDDA’s work. These measures 
span prevention, treatment, harm reduction and 
social reintegration. Historically, the focus of our 
work in this area has been to provide a descriptive 
analysis of services available. We will now 
complement this approach by extending the analyses 
to cover the availability, coverage and quality of 
interventions delivered across Europe.
In 2013, we will place greater emphasis on 
analysing two relatively undeveloped areas that 
are likely to become important for future prevention 
work in Europe: environmental prevention and early 
intervention. The latest available information will be 
collected on these two areas and made available in 
print, as well as on our website, reflecting the move 
towards increased online dissemination. 
For the prevention area, we will also initiate work on 
a new state-of-the-art scientific review on risk factors 
for drug problems and prevention interventions 
(EMCDDA Monograph). A considerable number 
of experts from different disciplines will contribute 
to this publication, in order to cover all areas in 
this field of research. This will include experts from 
basic research, epidemiology, prevention research 
and modelling. The final product is planned to be 
launched in 2014.
Monitoring demand reduction requires reporting on 
numbers of interventions, but also reporting on the 
availability, coverage and quality of interventions. 
Reporting on demand reduction is therefore based 
on analysis of data on numbers of interventions 
and estimates of needs as well as evidence of 
effectiveness. This information helps Member States 
to identify gaps in current service provision. It also 
facilitates better-informed choices between different 
types of interventions in a given situation. This 
approach enables us to monitor the availability 
and coverage of responses as part of an integrated 
model, thereby increasing its analytical value. 
Several activities in the 2013 work programme serve 
this purpose. 
To increase online dissemination, thematic pages 
on treatment, harm reduction, social reintegration 
and prison will be added to the online integrated 
response profiles. Treatment system maps will 
be consolidated, aiming to provide a better 
understanding of national treatment systems and total 
numbers of persons reached.
In 2013, a target-and-indicator framework will be 
developed for monitoring the implementation of the 
joint ECDC–EMCDDA ‘Guidance on the prevention 
of infectious diseases among people who inject 
drugs’. This target-and-indicator framework allows us 
to monitor how this guidance can improve practice. 
We will continue to prioritise our work to identify 
effective practice and encourage the sharing of 
information on ‘what works’. Ongoing dialogue with 
the scientific and practice community will ensure that 
we benefit from a state-of-the-art understanding of the 
available evidence for effectiveness. Our ongoing 
dialogue with the scientific community as well as 
experts working in the field will help us to choose 
the most relevant topics for our reviews of available 
evidence for effectiveness. This will be done in close 
collaboration with the Cochrane group and links with 
other international bodies will be further developed. 
Added value will be provided through inviting other 
appropriate networks to benefit from the EMCDDA’s 
technical infrastructure, thereby facilitating their work 
and allowing the agency to act as a hub for debate 
and information exchange. 
The Best practice portal will be redesigned, reflecting 
the move to increased online dissemination of our 
data. Knowledge translation has to use the different 
channels of information transmission for different 
target groups in the best way possible. While format 
and contents of papers and web pages providing 
guidance are further discussed and developed, a 
rational choice will be made on what to present 
where.
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Goal 2013–15: To support high-quality service development by producing information and analysis on 
demand reduction interventions and best practices
Specific objective 3.1: To monitor prevention provision, implementation and outcomes and to improve reporting 
on important areas where information resources are lacking
Priority interventions Planned activities Expected outputs/results
3.1.1. Provide an ongoing overview 
of drug prevention provision
 
3.1.1.1. Analyse and report findings 
from drug prevention area  
•	  Comprehensive web resources 
available and key analyses 
conducted
3.1.1.2. Disseminate key results •	 Presentations delivered at 
policy and scientific events and 
conferencess  
3.1.2. Develop analysis on 
environmental prevention factors
3.1.2.1. Provide updated information 
on environmental prevention
•	  Concept developed and EMCDDA 
paper published
3.1.3. Provide updated information on 
early intervention
3.1.3.1. Follow-up to the expert 
meeting on experience and evidence 
of interventions and methodologies 
used (brief intervention and 
motivational interviewing) 
•	  Meeting report and section on 
website developed 
3.1.4. Develop information on 
coordinated programming
3.1.4.1. Organise expert meeting 
on situation analysis on model 
coordination
•	  Meeting documents and 
presentations, available online
Specific objective 3.2: To improve the monitoring and analysis of treatment, harm reduction and social 
reintegration interventions and provide an integrated model for understanding service provision in Europe
Priority interventions Planned activities Expected outputs/results
3.2.1. Provide an ongoing overview 
of drug treatment, harm reduction and 
social reintegration
3.2.1.1. Analyse and report findings 
from responses area  
•	 Comprehensive web resources 
available and key analyses 
conducted
3.2.1.2. Develop thematic pages 
on treatment, harm reduction, social 
reintegration and prison responses 
(part of the Integrated response 
profiles)
•	 Up-to-date integrated response 
profiles
3.2.1.3. Finalise and publish analysis 
on residential care in Europe
•	  Paper on residential care in Europe 
published
3.2.1.4. Disseminate key results •	  Presentations delivered at 
policy and scientific events and 
conferences  
3.2.2. Implement the new treatment 
data collection and analysis strategy 
3.2.2.1. Support the finalisation of 
a first set of consolidated ‘national 
treatment system maps’ 
•	  New tool integrated into the 
reporting cycle
3.2.2.2. Develop a ‘European model 
treatment facility survey’, based on 
outcomes from an expert meeting and 
consultations with international peer 
organisations
•	 Expert meeting and supporting 
documents
•	  Model survey developed  
3.2.4. Develop and test health and 
social responses target-and-indicator 
frameworks
3.2.4.1. Draw up a target-and-
indicator framework template including 
process of consensus building on the 
targets
•	  Technical paper prepared, outlining 
common framework and process 
to produce target-and-indicator 
frameworks
•	  Expert meeting organised
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Priority interventions Planned activities Expected outputs/results
3.2.4.2. Produce target-and-indicator 
framework for monitoring the 
implementation of the joint ECDC–
EMCDDA guidance on the prevention 
of infectious diseases among people 
who inject drugs
•	  Target-and-indicator framework 
prepared in consultation with NFPs
3.2.5. Support the reporting on public 
health provision in Europe and assess 
gaps 
3.2.5.1. Provide data on European 
response indicators and treatment 
systems
•	  Consolidated data for reporting 
on drug-related issues for Dublin 
Declaration on partnership to 
fight HIV/AIDS in Europe and 
Central Asia and contribution to 
other international projects and 
initiatives, such as WHO–UN/
GARP (Global AIDS Response 
Progress)
Specific objective 3.3: To identify and support dissemination and knowledge exchange on best practices
Priority interventions Planned activities Expected outputs/results
3.3.1. Conduct state-of-the-art and 
evidence reviews 
 
3.3.1.1. Finalise in-depth topical 
review on treatment of cannabis-
related disorders
•	  In-depth topical review on treatment 
of cannabis-related disorders 
published (EMCDDA Insights series) 
3.3.1.2. Prepare in-depth topical 
review on hepatitis C treatment 
(EMCDDA Insights series) 
•	  Project report (publication in 2014)
•	  Accompanying guidelines for best 
practice on hepatitis C treatment 
(EMCDDA Manuals series) drafted
3.3.1.3. Prepare guidelines on drugs 
and prison
•	  Project report (publication in 2014)
3.3.1.4. Prepare state-of-the-art 
scientific review on drug prevention 
(EMCDDA Monograph series)
•	  Editorial group set up, outline 
defined, authors selected and 
contracted
3.3.1.5. Conduct overviews of 
evidence (meta-analysis of review) 
on specific interventions, and target 
groups
•	  Dedicated modules developed and 
Best practice portal updated
•	  Project report prepared  
3.3.2. Further develop the Best 
practice portal 
3.3.2.1. Revise the Best Practice Portal 
(BPP) website in line with the new 
communication strategy 
•	 Concept for revised structure 
developed 
3.3.2.2. Collaborate with top-level 
researchers in the field of knowledge 
translation science: DECIDE project (3)
•	 Concept for evidence-based 
selection and publication of best 
practice topics  
3.3.3. Disseminate knowledge on best 
practice
3.3.3.1. Support development of 
guidelines in Member States and 
facilitate networking with relevant top-
level organisations 
•	  Support and contact provided to 
NFPs (on request) 
3.3.3.2. Implement best practice 
dissemination strategy 
•	  Improved knowledge on best 
practices among NFPs and experts’ 
networks
•	 Knowledge on best practice 
disseminated through website, 
presentations at policy and 
scientific events and conferences
3.3.4. Conduct analysis to identify 
gaps in the evidence available for 
interventions  
3.3.4.1. Conduct systematic reviews 
of evidence and consult stakeholders 
to identify the gaps in the field of 
treatment for drug dependence 
•	  List of areas for further research 
developed
(3) DECIDE: Developing and evaluating communication strategies for supporting informed decisions and practice based on evidence.
25
II. Main areas of work in 2013
II.4. Monitoring drug supply and 
supply reduction interventions
Overview
The development of new indicators in the area of 
drug supply and supply reduction and the launch of 
the first strategic overview of drug markets in Europe 
will be the main highlights for our work in this area 
in 2013.
With a view to addressing the lack of comparable 
and reliable data on drug supply in general, and 
as a follow-up to the proposal prepared in 2012 
and the subsequent political decision to develop 
three key indicators in the areas of drug markets, 
drug-related crime and drug supply reduction, in 
2013 the EMCDDA will launch the development of 
sub-indicators (key composite indicators combining 
qualitative and quantitative data sets) covering drug 
seizures and drug production facilities. The process 
will start with a review of practices and proposals 
for improvements conducted with a limited group 
of experts and Europol. These two components 
have been prioritised because they are elements in 
both the key indicator on drug markets and the key 
indicator on drug supply reduction. Moreover, under 
the new policy cycle within the Standing Committee 
on Internal Security COSI) of the European Union, 
the EMCDDA has been tasked together with Europol 
to enhance the routine reporting system on seizures, 
and on dismantled illicit production sites in the field 
of synthetic drugs. Depending on the resources 
made available, it might be possible to launch the 
development of additional elements of the KIs, such 
as drug prices and drug purity and contents.
In addition, specific investments will be made in the 
area of drug supply reduction, where knowledge 
and indicator development is more limited. This 
will include the launch of a follow-up survey on 
‘drug squads’ in Europe, and taking further steps 
to strengthen the collaboration with Eurojust and 
investigate potential synergies in relation to the 
judiciary field.
In their ongoing effort to develop a more integrated 
and holistic perspective on drugs and crime, the 
EMCDDA and Europol will jointly produce a 
strategic overview placing drugs within the larger 
context of illicit markets and organised crime. This 
evidence-based report will provide all relevant 
stakeholders in the policymaking, law enforcement, 
prevention and academic communities with a 
coherent overview of the dynamic drug markets in 
Europe and the factors that impact on them. The 
report will be launched in early 2013.
In parallel to this request, the EMCDDA has been 
given, jointly with Europol, the task of implementing 
activities under the operational action plan (OAP) for 
2012–13 of the new policy cycle within the COSI of 
the European Union. The policy cycle is a structured 
priority-setting process for internal security. As long 
as internal security is a strategic priority of the 
European Union, drugs are, and are likely to remain, 
a key issue on the European security agenda. The 
EMCDDA will fulfil the tasks assigned to it under the 
OAP for 2013 in the field of synthetic drugs, and 
will take steps to participate in the definition of the 
priorities of the next policy cycle starting in 2014.
The main priorities outlined above call for the 
establishment of a sustainable European reference 
group of experts at national, European and 
international levels in the areas of drug supply 
and supply reduction. Particular efforts will need 
to be made to establish this group in 2013, taking 
into account that a broad range of expertise, 
together with flexible working modalities will be 
essential for the functioning of the group, in order to 
accommodate different objectives, including support 
to indicator development, contextualisation of routine 
data, updates on supply reduction interventions 
and identification of emerging trends. In addition, 
links with the law enforcement community will be 
reinforced through the EMCDDA’s training activities 
implemented in partnership with Cepol.
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Goal 2013–15: Provide the EC and the Member States with a comprehensive overview of the supply of illicit 
drugs into Europe and of the responses developed to respond to it
Specific objective 4.1: Develop European key indicators and complementary information resources for 
understanding drug markets, drug-related crime and drug supply reduction
Priority interventions Planned activities Expected outputs/results
4.1.1. Launch the implementation of 
the key indicators in the areas of drug 
markets, drug-related crime and drug 
supply reduction (following the second 
supply reduction conference and 
subsequent political decision) 
 
4.1.1.1. Launch development of a sub-
indicator ‘Drug seizures’  
•	  Expert meeting organised and 
potential elements of a draft 
standard reviewed
•	  Pilot study launched 
4.1.1.2. Launch the development 
of a sub-indicator ‘Drug production 
facilities’
•	  Expert meeting organised and 
potential elements of a draft 
standard on cultivation sites 
reviewed
•	  Pilot study on cultivation sites 
launched
•	  Coordinated approach with 
Europol for reporting of synthetic 
drug production sites and data 
validation
4.1.1.3. Launch the development of a 
sub-indicator ‘Drug prices’
•	  Potential elements of a standard 
monitoring instrument defined 
(internal working document)
4.1.1.4. Launch the development 
of a sub-indicator ‘Drug purity and 
contents’
•	  Potential elements of a standard 
monitoring instrument defined 
(internal working document)  
4.1.2. Map drug supply reduction 
activities, focusing on ‘drug squads’
4.1.2.1. Finalise the report of the first 
survey (conducted in 2011–12)
•	  Final report published
4.1.2.3. Conceptualise the follow-
up survey, define and test a 
methodological approach, and launch 
the survey
•	 Follow-up survey launched  
4.1.3. Develop understanding of the 
judiciary system as a data provider 
and an actor in drug supply reductio
4.1.3.1. Organise a working meeting 
with Eurojust to review potential 
synergies in the field of drug supply 
and supply reduction indicators
•	  Agreement on joint activities with 
Eurojust 
4.1.4. Develop cooperation with 
external partners on supply indicators 
(EC, Europol, Eurojust, Interpol, WCO, 
CoE/PG, Cepol, UNODC, etc.) 
4.1.4.1. Participate in institutional 
and technical meetings related to data 
collection, sources and indicators 
in the field of drug supply and drug 
supply reduction
•	  Coordination and data sharing on 
European indicators on drug supply
Specific objective 4.2: Establish networks in the area of drug supply and supply reduction 
Priority interventions Planned activities Expected outputs/results
4.2.1. Establish a European expert 
reference group on drug supply issues
 
4.2.1.1. Organise meeting with 
stakeholders and experts from Member 
States to propose a model for the new 
reference group  
•	  Objectives, organisation and 
membership of the reference group 
defined
4.2.2. Scale up training for the law 
enforcement community and promote 
exchanges 
4.2.2.1. Organise training activities 
(including exchanges) for the law 
enforcement community together with 
Cepol
•	  Training activities delivered with 
Cepol, experts from the Member 
States and Europol
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Specific objective 4.3: Produce a strategic analysis of drug supply and supply reduction in Europe 
Priority interventions Planned activities Expected outputs/results
4.3.1. Strengthen capacity to report 
on international developments 
 
4.3.1.1. Analyse EMCDDA needs in 
the field of drug supply and supply 
reduction, and propose a new tool to 
strengthen the EMCDDA’s capacity to 
report on international developments 
•	  Support tool conceptualised
4.3.2. Develop a data framework and 
input tools for drug seizures 
4.3.2.1. Develop a conceptual 
framework and input into Fonte data 
on drug seizures by type of law 
enforcement agency
•	  Historical data reconstructed
4.3.3. Produce strategic overview of 
drug markets in Europe
4.3.3.1. Support the launch of the first 
strategic overview of drug markets in 
Europe
•	 Joint publication with Europol 
launched
4.3.4. Produce joint analyses 4.3.4.1. Initiate steps to develop joint 
products with Eurojust
•	  Joint work programme prepared
Specific objective 4.4: Support the Internal Security Strategy of the EU (COSI) 
Priority interventions Planned activities Expected outputs/results
4.4.1. Carry out activities 1.5 and 
1.6 under the OAP for the policy cycle 
2012–13  
 
4.4.1.1. Co-organise with Europol 
an expert meeting on the reporting 
of drug seizures (see also activity 
4.1.1.1)
•	  Review of reporting methods and 
agreement on improvements to be 
made in the future
4.4.1.2. Co-organise with Europol 
an expert meeting on the reporting 
of dismantled drug production 
laboratories and related sites
•	  Agreement with Europol on the 
respective responsibilities in relation 
to the reporting of synthetic drug 
production sites
4.4.2. Support the definition of the 
following policy cycle and implement 
the activities for which EMCDDA has 
taken responsibility
4.4.2.1. Participate in the definition 
of the following policy cycle starting 
2014
•	 EMCDDA tasked within the OAP of 
the forthcoming policy cycle 
4.4.3. Develop cooperation with EU 
and international partners in the fields 
of home affairs and justice
4.4.3.1. Develop cooperation with EU 
and international partners in the fields 
of home affairs and justice
•	  Coordination and information 
exchange
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II.5. Monitoring new trends and 
developments and assessing the risks of 
new substances
Overview
In 2013, the EMCDDA, together with its partners 
in the Member States — the Reitox network of the 
early warning system (EWS) correspondents — and 
Europol and EMA will ensure continuous and robust 
implementation of the EWS. Rapid notifications/
warnings on new drugs, forensic and toxicological 
analytical data, longer-term monitoring and 
analysis of health and social risks, monitoring and 
analysis of illicit and ‘legal highs’ markets, as well 
as description of legal developments, will be key 
outputs of the system. As a main working tool of the 
EWS, the EMCDDA’s European database on new 
drugs (EDND) will be updated and expanded in a 
timely way. Where merited, a risk assessment on a 
new psychoactive substance (NPAS) will be carried 
out under the auspices of the EMCDDA’s Scientific 
Committee. The EMCDDA will strive to develop 
a greater capacity to identify, asses and share 
information on health and, where possible, social 
implications of the wide variety of new substances 
now becoming available. New data sources and 
techniques such as computational studies to explore 
the quantitative structure–activity relationships 
(QSAR) will be used to model the physico-chemical 
properties, pharmacology and toxicity of emerging 
NPAS which may pose concern at European level.
The EMCDDA in cooperation with the EMA will 
implement the exchange of data available through 
the Reitox EWS and the EU pharmacovigilance 
system, as set out in Article 28c of the new 
pharmacovigilance legislation. In consultation 
with the European Commission and in full 
compliance with the EMCDDA’s mandate, a 
conceptual framework for monitoring the misuse of 
medicines will be finalised and the feasibility of its 
implementation assessed. The EMCDDA’s monitoring 
of the misuse of medicines in the context of polydrug 
use will be taken forward through establishing a 
cross-unit project (CUP) resulting in a comprehensive 
conceptual framework and testing the feasibility of its 
implementation. 
To build on the global leadership of the EMCDDA in 
the field of monitoring new psychoactive substances, 
the possibility of organising the ‘Third International 
multidisciplinary forum on new drugs’ will be 
explored, in cooperation with international partners 
(in the context of the annual EWS meeting).
In 2013, the Council Decision 2005/387/JHA 
on the information exchange, risk assessment and 
control of new psychoactive substances is likely to 
be replaced by a new legal instrument. Therefore 
the existing networks, reporting and monitoring tools 
and instruments necessary for the implementation 
of the information exchange and risk assessment 
— including the EMCDDA database on new drugs 
— will need to be rapidly adapted and subsequently 
implemented and operationalised. As a first step, a 
new reporting form on new psychoactive substances 
will be developed in cooperation with Europol, as 
appropriate, followed by draft new operating EWS 
guidelines in line with the new legal instrument. 
Furthermore, in 2013–14, the European database 
on new drugs will be reconceptualised and 
redesigned in order to reflect the new system and to 
incorporate the newly designed project for matching 
new psychoactive substances to products containing 
them: project Match-It (4). By routinely collecting 
and sharing information from a variety of sources, 
including test purchase projects in the Member 
States, project Match-It will attempt to address 
one of the most pressing challenges hampering 
responses in this area: the practical difficulties of 
rapidly identifying which NPAS are contained in 
different products at a given time and location. This 
will increase understanding of and knowledge on 
the dynamic European marketplace where neither 
buyer nor seller may be accurately aware of what 
substances, or mixtures of substances, are being sold 
or consumed. Law enforcement agencies will also 
benefit from the results of this project.
Furthermore, in 2013–14 better coordination will 
be established between the EWS and the forensic 
(and toxicological) laboratory networks in order 
to enhance sharing of information and potentially 
reference materials and NPAS samples. This will also 
(4) In the EMCDDA 2013–15 strategy and work programme this project was called project Match; however, it has been renamed in order 
to avoid confusion with other similar project names in related fields.
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contribute towards achieving the relevant objective 
‘Synthetic drugs, including new psychoactive 
substances’ of the OAP for 2012–13 of the new 
policy cycle within the COSI of the European Union 
(see also Main area 4: Monitoring drug supply and 
supply reduction interventions).
Finally, monitoring new developments will be further 
enhanced through a reconceptualisation of the 
Internet snapshots to establish the availability of 
NPAS and, to the extent possible, their use, as well 
as through the routine implementation and fine-tuning 
of the EMCDDA trendspotter methodology and 
through exploring the potential of existing city-level 
networks to help assess emerging trends and threats 
at local level.
Previous EMCDDA efforts to explore and develop the 
monitoring of drug residues in wastewater will be 
furthered in order to establish by 2015 an indicator 
to estimate drug consumption at population level 
and gain an insight into the potential of the new 
methodology to size drug markets. This will be kick-
started during the first  international multidisciplinary 
conference on illicit drugs and wastewater organised 
by the EMCDDA.
Risks and conditionality: The achievement of some 
of the objectives and related activities is conditioned 
and dependent on the timing and provisions of the 
new legal instrument replacing Council Decision 
2005/387/JHA as well as on the demands and 
potential work load posed by any risk assessment 
exercise which may be launched in 2013.
Goal 2013–15: To provide a timely and sound information and analysis platform for identifying emerging 
trends and threats related to new psychoactive substances and their risks, new patterns of drug use and new 
developments in drug availability
Specific objective 5.1: To ensure that the information exchange and risk assessment mechanism on new 
psychoactive substances is of high quality and implemented in a timely and efficient manner
Priority interventions Planned activities Expected outputs/results
5.1.1. Implement the provisions of 
the Council Decision 2005/387/
JHA on the information exchange, 
risk-assessment and control of new 
psychoactive substances
 
5.1.1.1. Implement consistently the 
information exchange mechanism on 
new psychoactive substances (NPAS): 
the early warning system 
•	  Timely notification of new 
psychoactive substances to the 
Member States, EC, Europol and 
EMA
•	  Support (technical assistance, 
training, advice) provided to 
Member States, as needed
•	  Public health-related warnings 
issued (if relevant)
•	  Ad hoc additional data collection 
and analysis on new and 
established drugs of relevance
•	  New substance profiles prepared 
for all notified substances
•	  European database on new drugs 
(EDND) regularly updated
•	  3–5 computational quantitative 
structure–activity relationships 
(QSAR) models on selected NPAS  
5.1.1.2. Organise the annual meeting 
of the Reitox EWS network, with 
participation of Europol, EMA and the 
EC
•	  Meeting documents, presentations 
and results, available online
5.1.1.3. Implement longer-term 
monitoring of developments in NPAS 
and ‘legal highs’ products
•	  EWS progress and final reports 
from the national EWS (Reitox) 
network of the Member States 
collected, analysed and stored in 
the EDND
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Priority interventions Planned activities Expected outputs/results
5.1.1.4. Produce the EMCDDA–
Europol Annual report on the 
implementation of the Council 
Decision, based on collection and 
analysis of the 2012 data (Article 10 
report)
•	 EMCDDA–Europol Annual report 
on the implementation results 
submitted to the Commission, 
Council and the Parliament and 
published
5.1.1.5. Dynamically appraise all 
EDND information available and 
launch additional data collection on a 
NPAS (if appropriate)
•	  EMCDDA–Europol Joint reports on 
NPAS (if appropriate)
5.1.1.6. Implement multidisciplinary, 
scientifically sound risk assessment 
procedure (if requested)
•	  Studies/technical reports on the risk 
assessment prepared
•	  Risk assessment meeting of the 
Scientific Committee organised
•	  Risk assessment report from the 
Scientific Committee sent to the 
Commission and the Council and 
published
5.1.1.7. Consolidate existing 
EMCDDA online drug profiles
•	  Drug profiles consolidated and 
updated
5.1.1.8. Explore possibilities 
to organise third international 
multidisciplinary forum on new drugs, 
to increase the understanding of NPAS 
phenomenon at global level and the 
visibility of EU actions in this field
•	  Follow up international 
multidisciplinary forum on 
new drugs (co-)organised with 
international partners (in the context 
of the annual meeting of the Reitox 
EWS network)
5.1.2. Implement the provisions 
of Article 28c of the EU 
Pharmacovigilance (PhV) legislation
5.1.2.1. Implement the provisions 
of Article 28c of the EU 
Pharmacovigilance (PhV) legislation
•	  Information exchanged with 
EMA and the EU PhV system on 
medicines and substances with 
medicinal properties
•	  EDND (and if appropriate 
EudraVigilance) updated 
accordingly
5.1.3. Build up a formal forensic 
science and toxicology network (in 
line with OAP for 2012–13 of the new 
policy cycle within the COSI
5.1.3.1. Initiate the setting up of a 
formal forensic science and toxicology 
network 
•	  New potential partners identified
•	  Foundations of the network laid 
down
5.1.3.2. Implement information 
exchange with the European Network 
of Forensic Science Institutes (ENFSI)
•	  Structured cooperation between 
EMCDDA and ENFSI  
5.1.4. Help candidate and potential 
candidate countries prepare for future 
participation in the EWS and the 
Internet snapshot exercise
5.1.4.1. Provide training and support 
to selected countries for participating 
in the Internet snapshot exercise 
(within the instrument for pre-accession 
assistance IPA 4 project)
•	  Module on Internet snapshot 
delivered at the Intensive course on 
‘Looking at contemporary aspects 
of drug monitoring’ (see priority 
intervention 8.5.4)
•	  First Internet snapshot exercise in 
Balkan languages carried out 
5.1.4.2. Provide training and support 
to selected countries participating in 
the EWS (within IPA 4 project)
•	  Training organised for at least one 
IPA beneficiary country
•	  One expert from each IPA 4 
beneficiary participates in the 
meeting
•	  Experience exchange among 
regional partners organised in the 
margins of the meeting
5.1.5. Consolidate and improve 
the methodology for monitoring the 
Internet
5.1.5.1. Implement and further 
develop Internet monitoring exercises
•	  Internet snapshots conducted, data 
analysed and results disseminated
•	 Improved Internet monitoring 
methodology
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Priority interventions Planned activities Expected outputs/results
5.1.6. Support the consolidation 
of information on the content of 
products by implementing a tool that 
matches ‘legal high’ products to new 
psychoactive substances (project 
Match-It)
5.1.6.1. Develop the IT tool •	  Tool in suitable form for operational 
use available and piloted
5.1.7. Pilot monitoring of misuse of 
medicines (in the context of polydrug 
use and PhV)
5.1.7.1. Finalise conceptual 
framework for monitoring misuse of 
medicines
•	  Comprehensive conceptual 
framework for monitoring misuse of 
medicines and testing the feasibility 
of its implementation
Specific objective 5.2: To adapt and implement the information exchange and risk assessment mechanism on 
new psychoactive substances to new legal and institutional requirements 
Priority interventions Planned activities Expected outputs/results
5.2.1. Assist the Commission and 
the Council with the preparation of 
new legislation to replace the Council 
Decision (if requested)  
 
5.2.1.1. Prepare technical reports 
and/or provide support (if requested)
•	  EMCDDA contribution to the 
preparation of new legislation: 
technical reports drafted and/or 
assistance (as requested)
5.2.2. Implement the new legal 
instrument and adapt the existing 
networks, reporting and monitoring 
tools and instruments to new legal and 
institutional requirements 
5.2.2.1. Adapt the existing networks, 
reporting and monitoring tools 
and instruments necessary for the 
implementation of the information 
exchange mechanism to new legal 
and institutional requirements
•	  New EWS guidelines 
conceptualised
•	  Structure of the EMCDDA–Europol 
Annual report, Reporting form on 
new psychoactive substances, EWS 
progress and final biannual reports, 
and Joint report questionnaire 
adapted
•	  Extended network conceptualised; 
new potential partners identified; 
foundations of the network laid 
down 
5.2.3. Develop and implement the 
new EDND adapted to new legal and 
institutional requirements
5.2.3.1. Develop the new EDND •	  Draft concept and structure of the 
new database prepared
Specific objective 5.3: Facilitate the development of early responses to potential threats by strengthening the 
systems for identifying, tracking and understanding new and emerging trends in drug use, availability and 
adverse consequences
Priority interventions Planned activities Expected outputs/results
5.3.1. Improve monitoring of new 
drugs and links with epidemiology 
data sources and expert networks   
5.3.1.1. Contribute to the development 
of the new drugs component in GPS 
and ESPAD (see activity 2.1.1.2.)
•	  Contribution to the new European 
Model Questionnaire (EMQ) 
module on ‘new drugs’ 
5.3.2. Increase the capacity to monitor 
emerging trends 
5.3.2.1. Improve and consolidate the 
trendspotter methodology
•	  Trendspotters meeting organised
•	  Case study published (EMCDDA 
Updates) 
5.3.2.2. Develop a network of local, 
city-level monitoring
•	  City network that helps assess 
emerging trends and threats 
established
5.3.2.3. Consolidate the rapid 
response team (RRT)
•	  EMCDDA rapid response team 
consolidated and operational
•	  Rapid assessment and response 
(RAR) on key issue(s) conducted 
5.3.3. Explore the potential of 
wastewater analysis as an indicator to 
estimate population drug consumption
5.3.3.1. Implement follow-up of 
meetings and studies  
•	  The ‘Testing the waters’ conference 
organised 
•	  Conference documents and results 
available online 
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II.6. Improving Europe’s capacity to 
monitor and evaluate policies
Overview
Since its creation, the EMCDDA has monitored 
various aspects of drug policies including drug 
laws, drug strategies and action plans, drug 
policy coordination bodies, drug policy evaluation 
mechanisms and drug-related public expenditure. A 
database (European legal database on drugs, ELDD) 
and network of legal correspondents constitute the 
main resources supporting the EMCDDA’s reporting 
on drug laws.
The monitoring of national drug strategies and 
national coordination bodies has up to now relied 
exclusively on data collection activities with the 
national focal points but will now be enhanced, with 
the use of external experts and some small-scale 
studies planned. The evaluation of national drug 
strategies has relied both on data provided by the 
national focal points and on specialist information 
from two technical meetings organised in 2008 and 
2010. Routine monitoring in this area shows a rapid 
increase in the number of EU Member States that 
now evaluate their strategy or action plan.
Over the last five years, the EMCDDA has invested in 
monitoring drug-related public expenditure. The data 
available are limited, however, and not sufficient to 
obtain a good European picture and make reliable 
comparisons between countries. As a consequence, 
we have developed a new, more delineated strategy 
whereby specific areas of expenditure will be 
identified and estimated separately.
In 2015, the EMCDDA will publish its first 
monograph on drug policies. Preparatory work in 
2013 includes the development of an outline, the 
launch of a call for tender for an external editor, 
and the organisation of a first meeting to explore 
current drug policy typologies and classifications. 
The results of this meeting will feed into one of the 
chapters of the monograph. In addition, several 
studies will be conducted in 2013 in order to further 
explore different aspects of current drug policies. 
These studies include: a historical review of the 
national drug policy of Poland (as part of the series 
on national drug policy profiles); a study on typical 
trafficking penalties that will be complemented by a 
comparison of existing laws; a review and analysis 
of the drug policies of large European cities; and 
an exploration of trends in drug-related public 
expenditure following the economic recession and 
the associated budgetary cuts in some of the EU 
Member States.
A new EU drugs strategy (2013–20), complemented 
by two 4-year action plans, is due to be adopted 
in the coming months. As in the past, the EMCDDA 
will provide, on request, data and support for the 
progress reviews and evaluations of these drug 
policy documents. Member States increasingly 
request methodological support and expertise from 
the EMCDDA in the framework of evaluating their 
national drug strategies or action plans, the drafting 
of new laws or regulations or the estimation of drug-
related expenditure at national level. The EMCDDA 
will continue to offer support in these areas by 
providing overviews of existing practices in Europe 
and abroad. A study on the costs of courts for drug 
law offenders might be conducted if the feasibility 
study conducted in 2012 suggests that it is possible 
to estimate costs in this area with a sufficient level of 
confidence.
Another development planned to improve the 
quality of data and analysis in the drug policy area 
will be to strengthen the existing standing expert 
networks. The scope of the legal correspondents’ 
expert meeting will be enlarged to take in a broader 
policy agenda, covering legislative and strategic 
developments as well as public expenditure.
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Goal 2013–15: Improve the understanding of European and global policy developments by providing 
relevant and timely drug policy data, analysis and expertise
Specific objective 6.1: Develop European and global drug policy monitoring and analysis
Priority interventions Planned activities Expected outputs/results
6.1.1. Review current knowledge on 
key drug policy issues and challenges
6.1.1.1. Develop a state-of-the-art 
scientific review on drug policy 
challenges for the twenty-first century 
(EMCDDA Monograph series)
•	  Preparatory work conducted and 
call for tender launched  
6.1.1.2. Organise expert meeting on 
drug policy typologies and taxonomies
•	  Technical/scientific paper prepared
•	  Meeting documents and results 
informing EMCDDA outputs (e.g. 
drug policy paper, scientific 
article, monograph chapter or 
website section) or activities (e.g. 
monitoring of drug strategies)
6.1.2. Examine different models 
of drug policy to provide a better 
understanding of current policy 
options and support decision-making 
processes
6.1.2.1. Conduct study on drug-
trafficking penalties
•	  Project report prepared (EMCDDA 
publication in 2014)
6.1.2.2. Develop drug policy profiles •	  Drug policy profile on Ireland 
published
•	  Drug policy profile on Poland 
prepared 
6.1.3. Examine drug policies at the 
local level
6.1.3.1. Conduct analysis of city-level 
drug policies
•	  Drug policy paper on drug policies 
of large cities published
6.1.4. Analyse the impact of the 
economic recession on drug policies
6.1.4.1. Conduct analysis of trends in 
drug-related public expenditures
•	  Drug policy paper on trends in 
drug-related expenditure published
6.1.5. Provide data and expertise for 
the evaluation of the new EU drugs 
strategy and its action plans, and 
of other relevant EU legislation or 
activities
6.1.5.1. Support the EU in the follow-
up and evaluation of its drug strategy, 
action plans and other initiatives (on 
request)
•	  Data and expertise in the areas of 
drug policy evaluation provided at 
EU level 
6.1.6. Support Member States’ 
activities in the area of drug policy 
evaluation
6.1.6.1. Support Member States 
when developing and implementing 
an evaluation of their national drug 
strategy and/or action plan (on 
request) 
•	  Technical support provided on 
request and within available 
resources 
6.1.6.2. Support Member States when 
developing and implementing methods 
to estimate drug-related public 
expenditures (on request)
•	  Technical support provided on 
request and within available 
resources   
6.1.6.3. Provide Member States or EU 
institutions with an overview of drug 
laws or drug policies (on request)
•	  Technical support provided on 
request and within available 
resources  
6.1.6.4. Disseminate key results and 
technically support European policy 
debate on drug issues 
•	  Presentations and technical 
contribution delivered at scientific 
congresses and institutional 
meetings 
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Specific objective 6.2: Strengthen European networks in drug law and drug policy analysis
Priority interventions Planned activities Expected outputs/results
6.2.1. Strengthen network of legal and 
policy correspondents to improve data 
collection, data validation and data 
analysis in the drug policy area
6.2.1.1. Organise the legal and 
policy correspondents’ meeting
•	  Improved quality of the data and 
analysis in the drug policy area, 
through enlarging participation 
of experts and increased focus on 
analysis
•	  Meeting report and analysis 
available online   
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II.7. Scientific coordination, research 
and content support
Overview
An ongoing commitment to improving the scientific 
quality of our work is a prerequisite for fulfilling 
our role as a centre of excellence for the collection, 
analysis and dissemination of drug-related 
information. It is therefore a primary objective for 
scientific management and coordination.
The agency’s focus on quality assurance will require 
new internal mechanisms to ensure that scientific 
and methodological standards are defined and met. 
In 2013, we will initiate the work on a protocol 
for developing EMCDDA guidelines and handling 
requests for scientific advice. The main output of 
this work will be a declaration of methods adopted 
by the EMCDDA to ensure that the best and most 
systematic approach is used when EMCDDA 
guidelines are developed and/or recommendations 
in the drug addiction field are made.
In 2013, the EMCDDA will continue to formalise 
and develop its programme of training activities and 
related resources. Dissemination of information is at 
the core of the EMCDDA’s functioning, and providing 
training is one way to inform experts at different 
levels about the EMCDDA’s findings and results. 
Training activities developed at the EMCDDA cover 
a broad area of initiatives (from academic-orientated 
training and capacity-building projects to in-house 
traineeship opportunities). To ensure efficiency and 
minimise costs, an integrated approach is envisaged, 
with common materials developed for multiple 
purposes, and training activities linked where 
possible to expert meetings. While the capacities 
of the agency are limited in this area, collaboration 
with external providers of training can make the 
EMCDDA’s input functional and effective.
A priority in 2013 will be the continuous 
development, quality and coherence of the 
EMCDDA’s information collection and reporting 
system. We have recently reviewed this, and a 
number of improvements are planned to working 
practices. Given that the data collection capacity is 
finite and dependent on national activities, ongoing 
review of existing data demands and careful scrutiny 
of new requests are needed to ensure that demands 
upon the system do not exceed capacity.
The EMCDDA has a mission to provide its audiences 
with high-quality scientific work. This requires internal 
coordination and quality control processes, as well 
as external support, for both the scientific editing and 
the peer review of our products. The EMCDDA will 
also implement a new Annual report concept and 
web contents that will require new coordination and 
quality control processes. To increase our capacities 
in scientific coordination and content support, the 
EMCDDA will explore the possibility of working with 
scientists who can provide support for the editing of 
our publications. Another area of exploration will 
be the possibility to have a group of external peer 
reviewers to assess and improve the quality of our 
publications. A set of guidelines will be developed 
to allow these external partners to provide their peer 
review.
Transversal activities will be supported structurally by 
the creation of new CUPs (cross-unit projects). CUPs 
are established formally, have specific objectives 
and a timeframe, but provide a flexible mechanism 
for encouraging cross-unit work. The following CUPs 
are envisaged: CUP misuse of medicines, CUP 
trendspotting and CUP quality assurance. In addition 
to these new CUPs, in view of implementation of 
the new treatment data collection and monitoring 
strategy, it was decided to continue the work of the 
treatment CUP in 2013.
An active link with the scientific world outside the 
EMCDDA will be kept through many activities. 
Amongst them are the collaboration with studies 
in our field of responsibility, especially EU funded 
research such as ALICE-RAP and ERANID; monitoring 
of drug research in the Member States with the help 
of the Reitox national annual reports; providing 
input for a rational selection of research studies for 
funding; and publishing contributions of EMCDDA 
staff in scientific journals.
36
EMCDDA work programme 2013
Goal 2013–15: To produce high-quality scientific work through efficient working practices
Specific objective 7.1: Ensure the coordination of scientific activities so that resources are efficiently used, 
objectives are achieved and quality control of outputs is maintained
Priority interventions Planned activities Expected outputs/results
7.1.1. Improve handling of requests 
for scientific advice and opinion
7.1.1.1. Prepare methodological 
paper on procedure for developing 
EMCDDA guidelines and handling 
requests for scientific advice 
•	  Methodological paper available on 
EMCDDA guidelines and handling 
requests for scientific advice 
(internal working document)  
7.1.2. Develop EMCDDA strategy on 
training for external audiences and 
coordinate training activities
7.1.2.1. Analyse pilot solutions for 
developing an EMCDDA academic 
training framework
•	  Concept paper on options, models 
of organisation and financial 
implications
7.1.2.2. Initiate work on development 
of integrated training strategy 
•	  Concept paper on integrated 
training strategy 
7.1.2.3. Organise the 2013 Summer 
School: ‘Drugs in Europe: supply, 
demand and public policies’, in line 
with work on integrated training 
strategy
•	  Summer school organised and 
training material available 
7.1.2.4. Collaborate with and provide 
input into EC-funded and academic 
training projects
•	  EMCDDA contribution to European 
Master in Drug and Alcohol Studies 
(EMDAS), European Society for 
Prevention Research (EUSPR), Initial 
training network (ITN), Marie Curie 
fellowships 
7.1.4. Ensure the coherence of the 
overall reporting system 
7.1.4.1. Implement the follow-up 
action plan systemic review of tools 
•	  Action plan for implementation of 
systemic review of tools operational
7.1.5. Support the production of high-
quality scientific content
7.1.5.1. Provide scientific assistance 
and quality checks for selected 
EMCDDA publications
•	  Scientific aspects required for 
overall quality control framework 
developed and implemented
•	  Strategy for supporting scientific 
publishing implemented
•	  Support provided for content 
production (pre-editing), including 
developing pool of external 
scientific writers and provision 
of scientific writing for EMCDDA 
publications (articles, selected 
issues, the new Annual report)
7.1.5.2. Implement peer review 
system (in consultation with Scientific 
Committee)  
•	  External peer review team, and 
guidelines, developed
•	  Increased number of publications 
peer reviewed  
7.1.5.3. Support production of 
publications in scientific journals 
•	  Stable or increasing number of 
publications in journals    
7.1.5.4. Develop a concept paper 
on the ethical aspects related to 
monitoring drugs 
•	  Concept paper prepared   
7.1.6. Coordinate internal information 
exchange on new developmental 
areas and/or transversal projects
7.1.6.1. Set up CUPs (cross-unit 
projects) on misuse of medicines, 
trendspotting and quality assurance, 
and continue the treatment CUP 
•	  New CUPs set up and operational; 
meetings organised and supporting 
documents available (see also 
priority interventions 2.3.4, 3.2.2, 
5.1.7 and 5.3.2)
•	  Coordinated work in the areas of 
misuse of medicines, trendspotting, 
quality assurance and treatment  
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Specific objective 7.2: Support drug-related research, audit key developments and promote the use of research 
findings
Priority interventions Planned activities Expected outputs/results
7.2.1. Monitor and disseminate 
developments in drugs research
7.2.1.1. Update and improve public 
website and intranet research page
•	  Improved online access to EU-
funded research findings
•	  Annual audit of important research 
developments
7.2.2. Provide input to the 
development of the EC research 
agenda 
7.2.2.1. Develop EMCDDA 
methodology for advising on 
research priorities, in respect of the 
priority-setting prerogatives of the EU 
Institutions  
•	  Methodology endorsed by the 
Scientific Committee 
7.2.2.2. Support the European 
Research Area Network on Illicit Drugs 
(ERANID) 
•	  EMCDDA input to ERANID 
7.2.3. Further develop collaboration 
with the scientific community through 
dissemination of findings and 
increased contribution to relevant 
events
7.2.3.1. Organise the Scientific paper 
award
•	  Event organised; acknowledgement 
of scientific publishing in the 
drugs field; increased visibility of 
EMCDDA (as measured through 
media coverage)  
7.2.3.2. Increase collaboration with 
projects and initiatives developed by 
the scientific community: Addiction 
and Lifestyles in Contemporary Europe 
— Reframing Addictions Project 
(ALICE-RAP), ERANID, Links in the 
Chain (LINKSCH), EMDAS, European 
Federation of Addiction Societies 
(EUFAS), International Confederation 
of Alcohol, Tobacco and other Drugs 
Research Association (ICARA), EU 
universities
•	  Increased input, visibility and 
standing of EMCDDA outputs 
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II.8. Cooperation and collaboration 
with key partners
Overview
Cooperation with key external partners, namely with 
EU institutions and bodies, national policymaking 
bodies, international organisations, civil society 
and third countries, is a cornerstone of the agency’s 
mandate and will represent an important part of the 
EMCDDA’s work over the next three years.
The 2013–15 strategy commits the agency to 
strengthening and enhancing cooperation with 
European, national and international partners. In 
line with one of the agency’s top-level commitments 
and the new communication strategy, special focus 
will be given to improving the EMCDDA’s service 
culture towards an even more customer-orientated 
approach. This involves becoming more proactive in 
order to better identify/review/update the needs of 
policymakers and other EMCDDA stakeholders and 
improving responsiveness (better-quality and more 
timely replies).
The objective of international cooperation activities is 
to provide support and EMCDDA expertise in drug-
related fields. It is also to participate in international 
projects and have a coordinated and coherent 
approach to developments at global and regional 
level.
Resources are limited and the selection of partners, 
working areas and priorities need to be clearly 
defined. Work in 2013 will therefore be based on 
existing working arrangements and cooperation 
agreements, in order to ensure that the defined 
priorities are accomplished and that resources 
are invested soundly. At the same time, the drugs 
situation is constantly evolving so the agency remains 
open to new areas and cooperation arrangements, 
provided that these are in line with the EU priorities, 
the EMCDDA international cooperation strategy and 
the internal planning framework.
The agency’s work with external partners is 
implemented in different areas and on various levels: 
institutional cooperation and content-related and 
core business-orientated activities.
At the institutional level, maintaining close 
cooperation and collaboration with the EU 
institutions, namely the European Parliament (EP), 
the Council of the EU and the European Commission 
(EC), remains one of our main priorities. The agency 
will continue to provide support, as required, and 
further consolidate its role as technical information 
provider at institutional meetings in the field of 
drugs, such as the Horizontal Drugs Group (HDG), 
the EU policy dialogues or the OAP within the EU 
internal security policy cycle. Exchange of views and 
information will be increasingly promoted through 
visits of members of the EP (MEPs) to the EMCDDA or 
meetings between the Director and MEPs in Brussels. 
As in previous years, the agency’s Annual report will 
be presented to the Civil Liberties, Justice and Home 
Affairs Committee (LIBE) of the EP and to the Justice 
and Home Affairs (JHA) Council. Regarding the EC, 
coordination will be ensured through meetings and 
regular contacts with the parent Directorate-General 
(DG) and content-related DGs. The EMCDDA will 
continue to provide technical advice and support 
the transfer of knowledge to the EC for the planning, 
execution and dissemination of information related 
to EC-funded drug-related projects. Furthermore, 
participation of a high-level EC representative in the 
launch of the 2013 Annual report is envisaged.
The EMCDDA will continue to provide support to 
the implementation and/or monitoring of policy 
documents and initiatives in the drugs field. One 
of the highlights in this area is the new EU drugs 
strategy 2013–20, expected to be adopted by the 
end of 2012, and the preparation of its action plan 
2013–16, for which the EMCDDA will provide 
support, as requested.
Cooperation and collaboration with key partners
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Another highlight is the work aiming to strengthen 
relations with the Member States, in particular with 
key national policymaking bodies. Building on the 
assessment of the status of cooperation with the 
Member States started in 2012, a cooperation/
communication policy with key national policymakers 
will be defined, with support from the NFPs. The 
new policy should contribute to making the work 
of the agency and of the NFPs more visible and 
more relevant for national stakeholders, therefore 
confirming their added value and helping to 
maintain the overall funding of national drug 
information systems.
Also at the institutional level, the EMCDDA will 
strengthen cooperation with other EU agencies in 
order to define and implement common positions, 
policies and working methods and tools. This will 
include participation in and contribution to the 
Heads of Agencies and inter-agencies technical 
and coordination networks and clusters, to ensure 
synergies and promote a common EU approach.
At the technical level, some important areas of work 
with external partners will be developed in 2013, 
mainly with other EU agencies and international 
organisations. These include: harmonisation of 
data collection (e.g. prison and drug supply areas); 
development of quality standards and practice in 
collecting drug-related information (with UNODC, 
Inter-American Drug Abuse Control Committee 
(CICAD) and ECDC); joint work on guidelines and 
recommendations for interventions and responses 
in the drug field (mainly with ECDC, Europol and 
WHO); coherence between the EMCDDA’s activities 
in non-EU countries and those implemented by 
(5) Acceding country: Croatia; candidate countries: Former Yugoslav Republic of Macedonia, Montenegro, Turkey; potential candidate 
countries: Albania, Bosnia and Herzegovina, Kosovo (as of 1 September 2012). This designation is without prejudice to positions on 
status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence.
(6) Algeria, Armenia, Azerbaijan, Belarus, Egypt, Georgia, Israel, Jordan, Lebanon, Libya, Moldova, Morocco, Occupied Palestinian 
Territory, Syria, Tunisia and Ukraine.
other global players, such as WHO, UNODC and 
UNAIDS; other joint publications, projects and 
expert meetings, as required.
With regard to cooperation with non-EU countries, 
in line with its mandate and consistent with the 
EMCDDA strategy for international cooperation, the 
EMCDDA’s work is structured around three groups 
of countries: acceding, candidate and potential 
candidate countries to the EU (5), the European 
Neighbourhood Policy (ENP) countries (6) and other 
third countries. Most of these activities are being 
developed in the context of EC-funded technical 
cooperation projects, such as the Instrument for 
Pre-Accession Assistance (IPA), or with the financial 
support of EC programmes such as the Technical 
Assistance and Information Exchange instrument 
(TAIEX), the Cooperation Programme between 
Latin America and the European Union on Drugs 
Policies (COPOLAD) and Central Asia Drug Action 
Programme (CADAP). 
For 2013, the main activities in order of priority 
are: (1) to improve the data collection and the 
quality of the information provided by NFPs, (2) 
to further develop a reference document linking 
in practical terms monitoring and planning/
organisation of services (using IPA funds), (3) to 
provide methodological support (upon request) to 
EU Member States that are drafting a new national 
strategy or that need support for evaluating their 
strategy/action plan, and (4) to share the EU 
experience and the EMCDDA know-how in this area 
in the EC-financed assistance programmes to non-
EU countries (acceding, candidate and potential 
candidate countries, ENP, COPOLAD, CADAP).
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Goal 2013–15: To support EU drug policy debate and effective actions and increased capacity for reporting 
on drug use in non-EU countries with an emphasis on countries which represent a priority for EU action in the 
drugs area
Specific objective 8.1: Coordinate, cooperate and provide technical support at the EU level 
Priority interventions Planned activities Expected outputs/results
8.1.1. Provide technical support to EU 
policy deliberations
8.1.1.1. Provide expertise and 
technical information to the European 
Commission, Council and Parliament
•	  Support for the European 
Commission, Council and 
Parliament provided (as requested)
•	  2013 EMCDDA Annual report 
presented to EU institutions (the 
LIBE Committee of the European 
Parliament and the JHA Council)
8.1.1.2. Consolidate the EMCDDA’s 
role of technical information provider 
in institutional drugs meetings such as 
the Horizontal Drugs Group (HDG); 
political dialogues with third countries; 
National drug coordinators; EU 
Presidency events  
•	  EMCDDA technical backstopping 
and support to policy debate at 
HDG and in other appropriate fora 
(as requested) 
8.1.1.3. Provide support to the EU 
drugs strategy 2013–20 and the 
preparation of its 2013–16 action plan 
(as requested) 
•	  To be defined based on the 
adopted EU drugs strategy 
2013–20 
8.1.1.4. Provide support for the 
implementation and/or monitoring of 
other policy documents and initiatives, 
such as the operational action plan 
(OAP) on synthetic drugs, EU HIV/
AIDS action plan 2009–13, EU 
alcohol strategy (as regards polydrug 
use), ECDC advisory group on 
monitoring HIV responses in Europe, 
etc. (as requested)
•	  Technical reports, reviews, 
presentations, etc. (as requested)  
8.1.2. Ensure effective collaboration 
with other EU agencies
8.1.2.1. Cooperate with other EU 
agencies, in order to define and 
implement common positions, policies 
and working methods and tools 
•	  Participation in the Heads of 
Agencies meetings; follow-up to the 
implementation of joint statements 
of the EP, the Council of the EU 
and the EC on issues related to 
decentralised agencies; comments 
and written contributions to issues 
common to EU agencies
•	  Participation in and contribution to 
inter-agency networks
•	  Participation in and contribution to 
the work of JHA agencies cluster  
8.1.2.2. Implement Memoranda of 
understanding (MoUs) and other 
working arrangements in force, 
exchange information and develop 
joint projects and working synergies 
with Europol, CEPOL, Eurojust, ECDC, 
EMA
•	  Work programmes and 
cooperation agreements endorsed 
and implemented
•	  EMCDDA–Europol multiannual 
work programme (2013–16) 
endorsed
•	  Joint publications produced
•	  Coordinated contribution to 
projects and initiatives in the drugs 
field
•	  Joint meetings and events 
organised 
8.1.2.3. Explore areas for cooperation 
with other EU agencies
•	  Framework for cooperation with 
other EU agencies established and 
developed (where appropriate)
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Specific objective 8.2: Improve dialogue with policy audience, civil society and relevant technical and scientific 
bodies 
Priority interventions Planned activities Expected outputs/results
8.2.1. Monitor key developments and 
improve information exchange with 
civil society partners
8.2.1.1. Participate in the EU HIV/
AIDS think tank meetings, the EU HIV/
AIDS civil society forum and the Civil 
society forum on drugs
•	  Dissemination of the EMCDDA’s 
expertise, findings and products, 
through presentations, inputs to 
technical meetings and discussions, 
invitations to civil society members 
to attend EMCDDA events
8.2.1.2. Promote participation of civil 
society partners, including NGOs, in 
activities developed under the IPA 4 
project
•	  Participation and contribution 
from civil society partners in 
project countries to IPA 4 technical 
meetings and publications  
8.2.2. Improve understanding of 
information needs and identify 
effective communication channels with 
national policy bodies
8.2.2.1. Develop and implement 
actions to further strengthen relations 
with the EMCDDA Member States 
and in particular with the key national 
policymaking bodies, and the 
Portuguese authorities 
•	  Report on the assessment of the 
status of cooperation with the 
Member States, with a view to 
better understanding the needs of 
national policymakers and what 
constitutes effective channels of 
communication for them
•	  Cooperation/communication policy 
with the key policymakers in each 
Member State, such as national 
parliaments and governments, 
defined (with input/support from 
NFPs, as needed)
•	  Ongoing collaboration with the 
hosting country authorities, namely 
with the Parliament, Government 
and Presidency of the Republic
Specific objective 8.3: Coordinate, cooperate and provide appropriate technical input to work conducted by 
international bodies in the drugs field
Priority interventions Planned activities Expected outputs/results
8.3.1. Provide technical input and 
information to international activities 
(in line with mandate and strategy)
8.3.1.1. Contribute to reports, expert 
meetings, international projects, 
trainings and seminars and exchange 
information with international partners 
and regional bodies (including 
UNODC, UNAIDS, WHO, Interpol 
and WCO, Pompidou Group and 
CICAD)
•	  Input to reports, meetings, projects, 
training activities and seminars
•	  Information exchange on 
trafficking routes and seizures with 
UNODC and other international 
organisations
•	  Technical support provided to 
the Member States and EC; side 
events organised with international 
partners during the session of the 
Commission on Narcotic Drugs 
(CND)
•	  Information exchange with 
international organisations in IPA 
4 and ENP countries, ensuring that 
interventions are complementary 
and mutually reinforcing
8.3.2. Support the development of 
coherent information standards and 
information resources at international 
level
8.3.2.1. Cooperate with major 
European and global partners to 
increase quality, comparability and 
coherence of data in international 
reporting 
•	  Input provided, contribution 
to expert groups on quality 
issues, data validation exercises 
conducted and codes harmonised 
(where possible) (see also priority 
interventions 1.2.2 and 3.2.5)
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Priority interventions Planned activities Expected outputs/results
8.3.3. Develop and implement joint 
work with key external partners
8.3.3.1. Implement existing 
arrangements and work programmes 
(with UNODC, CICAD, Pompidou 
Group, WHO) and continue 
exchange of expertise, know-how and 
information 
•	  Joint projects and activities 
implemented
•	  Joint work with WHO Europe in 
prison area and in the area of 
drug-related infectious diseases and 
harmonisation of data collections
•	  Joint article by EMCDDA and 
WHO Europe on coverage of harm 
reduction interventions in the EU 
Member States prepared
8.3.3.2. Strengthen the institutional 
relations and working arrangements 
with other international organisations 
and bodies
•	  Cooperation agreement with 
UNAIDS endorsed
Specific objective 8.4: To support capacity development and enhance the scientific value of drug monitoring 
activities within candidate (CC) and potential candidate countries (PCC) 
Priority interventions Planned activities Expected outputs/results
8.4.1. Consolidate institutionalisation 
of NFPs within CC and PCC
8.4.1.1. Support CC and PCC 
participating in IPA 4 in developing 
national action plans for drug 
information system 
•	  National action plans for drug 
information system approved in all 
IPA 4 participating countries 
8.4.1.2. Carry out annual 
coordination activities to measure 
progress in the establishment of NFPs 
or operation of the existing focal 
points in the IPA 4 countries
•	  Progress reports and action plans   
8.4.1.3. Provide technical 
and administrative support for 
implementation of IPA 4 project-related 
national activities in CC and PCC
•	  Better understanding of applicable 
EU/financial regulation and 
effective implementation of 
activitiesc
8.4.2. Foster scientific cooperation 
in relation to data collection, 
interpretation and analysis and 
accrue added value from cooperation 
activities
8.4.2.1. Exchange practices and 
knowledge on a specific scientific/
data collection topic, of common 
interest for all IPA 4 beneficiary 
countries
•	  Reitox academy organised and 
25 professionals from all IPA 4 
countries trained
8.4.2.2. Enhance participation 
of CC and PCC in the annual 
European expert meetings on key 
epidemiological indicators
•	  Data collection streamlined with EU 
standards and better analysis of 
available data
8.4.2.3. Provide support to CC and 
PCC for preparing their 2013 national 
reports
•	  Data from CC and PCC integrated 
into the EMCDDA Annual Report 
package and other relevant 
publications (on ad hoc basis)
•	  8 national reports/updates 
produced by CC and PCC
8.4.2.4. Share the EU experience 
and the EMCDDA know-how in 
monitoring and evaluation of national 
strategies in the EC-financed assistance 
programmes to non-EU countries
•	  Methodological support provided 
to countries developing new 
national strategies or evaluating 
their existing strategies/action 
plans (upon request, using IPA or 
ENP funds)
8.4.2.5. Liaise with EC services on the 
progress made by countries, and on 
obstacles to project’s implementation
•	  EC progress reports on CC and 
PCC informed by EMCDDA IPA 4 
activities
8.4.2.6. Prepare the first report on the 
Balkan region
•	  Report on Balkan region (IPA 4) 
prepared (publication in 2014)
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Specific objective 8.5: Support capacity development, information availability and exchange with interested 
ENP and other non-EU countries 
Priority interventions Planned activities Expected outputs/results
8.5.1. Launch the EMCDDA technical 
cooperation with interested ENP 
partner countries and Russia to 
improve knowledge base
8.5.1.1. Further develop and 
consolidate the cooperation network 
with ENP countries and Russia
•	  Interested countries have appointed 
their official correspondent to the 
EMCDDA and participate in the 
Reitox Week 
8.5.1.2. Organise the first activities 
of the future cooperation project in 
the participating countries (subject to 
approval of the project by the EC) 
•	  National kick-off meetings in 
participating countries, joint needs 
assessment reports   
8.5.1.3. Produce or update country 
profiles for selected ENP partner 
countries in close cooperation with the 
appointed national correspondents 
•	  6–8 country profiles produced/
updated on the EMCDDA website
8.5.1.4. Organise seminars, with 
financial support from TAIEX, to 
increase knowledge about the 
EMCDDA and drug-related data 
collection in the EU, among experts in 
selected ENP countries
•	  Regional seminar organised (in 
Moldova) for 30 participants from 
East ENP countries
•	  National seminar on the drug 
information systems organised (in 
Israel) for 20 national experts
•	  Scientific support provided to 
experts from selected countries 
8.5.2. Exchange information, working 
practices and methodology on the 
identification of new psychoactive 
substances with other interested 
regional and national monitoring 
systems
8.5.2.1. Exchange information, 
working practices and methodology on 
the identification of new psychoactive 
substances with other interested 
regional and national monitoring 
systems 
•	  Comprehensive information 
package disseminated in ENP 
countries
•	  Participation of selected countries in 
the Internet snapshot exercise 
8.5.3. Provide ad hoc scientific 
support to ongoing EC regional 
programmes
8.5.3.1. Provide input for the CADAP 
5 project, and drafting of CADAP 
6 project (in line with the EMCDDA 
mandate and priorities in area of 
international cooperation)
•	  EMCDDA input for CADAP 5 
acknowledged in the project 
evaluation report
•	  The EMCDDA’s role and expected 
contribution clearly defined in the 
CADAP 6 project document
•	  Scientific support provided to 
COPOLAD, CADAP, etc. (subject to 
resources)
8.5.4. Develop training materials 
and training modules on EMCDDA 
standards
8.5.4.1. Organise an intensive course 
on contemporary issues in drug 
monitoring 
•	  5-module training package 
produced and training with 
participation of at least 30 
participants from CC and PCC 
implemented
8.5.5. Promote EU model for NDOs 
and National Drug Information 
Systems
8.5.5.1. Further promote the role 
of European and National Drug 
Observatories as key information 
providers for policy planning, 
monitoring and evaluation
•	  A reference document explaining 
in practical terms how to link 
monitoring and planning/
organisation of services for EU 
and non-EU NFPS is prepared 
(contribution to Handbook II, to be 
published in 2014, with IPA funds) 
8.5.5.2. Organise second Reitox 
week with participation of EMCDDA 
Member States, CC and PCC, ENP 
countries and Russia
•	  Extended Reitox network meets 
once per year and contributes to 
the improvement of data collection 
in partner countries
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Supporting the achievement of results
II.9. Communicating the EMCDDA’s 
findings to external audiences
Overview
Communication is a core activity of the EMCDDA 
both in supporting its role as an information 
agency and in helping further its reputation as the 
‘reference point on drugs in Europe’. The updated 
communication strategy, adopted in 2012, sets 
out the fundamental principles for communicating 
our knowledge and presents the tools available to 
build and nurture relations with our stakeholders, 
target audiences and partners. Activities in 2013 
will be guided by this strategy which aims to ensure 
that communication activities are not an isolated 
function at project-end, but an integral part of the 
agency’s scientific and technical activity. At a time 
of heightened need for an efficient use of resources, 
this integrated and multidisciplinary approach pools 
scientific and technical expertise to produce pertinent 
and cost-efficient results.
An action plan, developed at the end of 2012, 
details the follow-up work needed to implement the 
strategy. 
Applying an integrated approach espoused by the 
new communication strategy requires significant 
changes to the way we work. In 2013, we will 
develop the practices and workflows with the 
scientific units to enable the end product and its 
appropriate communication channel to be identified 
at an early stage.
We will also tackle timeliness, which is highlighted 
in the 2013–15 work programme as an area for 
focus. A clear definition of the product at the outset 
and increased dialogue throughout production 
will contribute to a faster turnaround of findings. 
However, the activity that will have the most 
significant impact here will be the release of our 
annual analysis on the state of the drugs problem 
five months earlier, in June instead of November. 
The reconfigured Annual reporting package will 
consist of a shorter trends report (printed and 
available in 22 languages) supported by online 
topic-based ‘spotlights’, a statistical bulletin and 
country overviews. Adapting work processes to meet 
this deadline and investing in the necessary design 
and technical developments to make these products 
dynamic and interactive will be a priority in 2013.
The EMCDDA website is the agency’s primary 
means of communicating across all target audiences 
and is the key to reinforcing the agency’s profile as 
the primary source of drug information in Europe. 
Some important parallel developments are planned 
for 2013. We will review all content on the public 
website, draw up an inventory and identify follow-
up actions. Work will be undertaken to select a 
new content management tool and the migration 
of selected content will begin. An improved quality 
assurance system will be introduced to ensure that 
quality checks are as rigorous as for other EMCDDA 
products. We will develop a more dynamic website 
through increasing the number of interactive 
elements.
Keeping abreast of the needs of our customers 
requires a regular review of how we are serving 
them and by what means. The utility of the existing 
EMCDDA product types was analysed under the 
systemic review (conducted in 2012) and the 
2013–15 work programme identifies some new tools 
needed to convey results. In 2013, we will adapt the 
EMCDDA product range in line with these findings 
and in the context of a general brand refresh.
In 2013, working closely with all units, we will 
complete a mapping exercise of our stakeholders 
and target audiences. The results of this exercise 
will provide the basis for drawing up audience 
engagement strategy to be implemented in the 
coming years. 
Media interest in EMCDDA results continues to grow. 
In 2013, we will develop our ‘heads up’ approach 
(advance warning) so the media can plan the 
coverage of our work better. We will also develop 
our use of video materials.
The EMCDDA’s linguistic policy is based on a 
thorough assessment of need, privileging quality 
over quantity. Guidelines and instruments will be 
developed to assist in making sound financial 
decisions that achieve maximum impact. 
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The products list for 2013 is comprehensive and 
innovative (new joint publication with Europol on EU 
drug markets). We will continue to use the Editorial 
Board to prioritise and pace the work, and the 
products follow-up meeting to plan resources and 
keep abreast of production. 
The channels at our disposal to promote EMCDDA 
work results include the web, publications and 
print products, events and conferences, the media, 
audiovisual material and social media. These 
multiple, and often converging, information channels 
demand strong synergies between the different 
specialities in the communication team. Such cross-
functional working allows the agency to shape and 
repurpose content efficiently and mobilise a mix of 
options, with the ultimate goal of maximising the 
impact for the customer. Exploring new dissemination 
options and tools is also part of our commitment to 
efficiency, which requires us to further rationalise 
participation in external events, in line with the 
existing resources and priorities. 
We will continue to provide reliable and efficient 
information, library and documentation services 
supporting the research needs of the scientific staff.
We will use internal communication activities to 
support and develop the cross-unit collaboration that 
needs to take place for the communication strategy 
to be successful. 
Goal 2013–15: EMCDDA information and analyses of high quality reach their intended audience in a timely 
and cost-efficient manner
Specific objective 9.1: Implement the integrated communication strategy and action plan (adopted in 2012)
Priority interventions Planned activities Expected outputs/results
9.1.1. Develop procedures to integrate 
communication perspective at product 
conception
9.1.1.1. Define practices and 
workflows with scientific units to 
ensure integrated approach to product 
conception
•	  Improved planning and shaping of 
products upstream (see also priority 
intervention 9.2.1)  
9.1.1.2. Improve scheduling of outputs •	  Better-paced and better-targeted 
launches 
9.1.2. Redesign product range to 
reflect new EMCDDA strategy and 
work programme (brand refresh)
9.1.2.1. Adapt product range to 
reflect systemic review findings and 
commitments set out in 2013–15 work 
programme
•	  A rationalised and balanced 
products mix with cost savings and 
efficiency gains
9.1.2.2. Start work on brand refresh 
including redesign of publications 
(titles and series) 
•	  Refreshed corporate identity for 
EMCDDA products 
9.1.3. Implement revised linguistic 
policy
9.1.3.1. Apply new translation policy 
to EMCDDA products 
•	  Procedures, guidelines and 
instruments developed to support 
translation management  
9.1.3.2. Conduct needs assessment 
to select products that represent good 
value for translation 
•	  More strategic choices made to 
achieve maximum impact (taking 
into account new language groups, 
in line with the activities in the area 
of international cooperation — see 
also Main area 8)
9.1.3.3. Continue to work with 
national focal points on the 
terminology/glossary project 
•	  New terms with agreed and 
translated definitions uploaded 
to IATE (the EU’s multilingual term 
base)
9.1.4. Revise media relations strategy 
in line with new communication 
strategy (see also priority intervention 
9.4.3 below)
9.1.4.1. Revise media relations policy 
document and action points
•	  Action points for 2013–15 
prepared and 2013 action points 
implemented 
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Priority interventions Planned activities Expected outputs/results
9.1.5. Engaging better with audiences 9.1.5.1. Integrated cross-unit 
consultations to identify key 
stakeholders and target groups
•	  Mapping exercise completed and 
analysed and planning prepared
9.1.5.2. Start developing an audience 
engagement strategy
•	  Step 1 of strategy completed 
(identify, analyse, plan)
9.1.6. Monitor and evaluate the 
impact of communication activities
9.1.6.1. Continue routine work in the 
areas of dialogue and evaluation and 
begin to define indicators
•	  Better knowledge of outreach and 
impact gained in order to inform 
future EMCDDA strategies
•	  Performance indicators defined 
to allow better measuring of the 
impact of communication activities
9.1.7. Develop an internal 
communication strategy and 
associated activities to underpin new 
strategy
9.1.7.1. Define procedures for 
communicating on specific content 
areas
•	  Action plan and procedures 
endorsed and implemented
9.1.7.2. Improve and develop internal 
communication channels
•	  Improved knowledge-sharing tools 
available
Specific objective 9.2: Publish high-quality and timely products in line with targets committed to in the 2013–15 
work programme 
Priority interventions Planned activities Expected outputs/results
9.2.1. Assure publication, launch and 
dissemination of EMCDDA products
9.2.1.1. Deliver timely editing, 
production, dissemination and 
promotion services
•	  Planned products published, 
launched and disseminated (see list 
of outputs) 
9.2.1.2. Improve quality control in 
the production process of EMCDDA 
products 
•	  Clear procedures and workflows for 
content production and publication 
in place  
9.2.1.3. Hold monthly follow-up on 
product meetingse
•	  Better planning of resources and 
monitoring of production
•	  Monthly meetings organised and 
minutes disseminated internally
9.2.1.4. Hold monthly editorial board 
meetings
•	  Better prioritisation of products and 
planning for release
•	  Monthly meetings organised and 
minutes disseminated internally 
9.2.2. Reconceive and reshape 
printed Annual report 
9.2.2.1. Revise the set of Annual 
reporting products 
•	  Streamlined and electronically 
integrated Annual report package  
9.2.2.2. Conceive, write, produce 
and launch concise Annual report 
concentrating on trends  
•	  Annual report in new format 
successfully produced and launched 
in June
9.2.2.3. Conceive set of online topic-
based ‘spotlights’
•	  Online product showcasing topical 
content
9.2.2.4. Prepare Country overviews in 
consultation with NFPs
•	  30 Country overviews published 
online, as part of the Annual report 
package  
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Specific objective 9.3: Increase the relevance and impact of the EMCDDA’s online presence
Priority interventions Planned activities Expected outputs/results
9.3.1. Develop web content in line 
with integrated communication 
strategy  
9.3.1.1. Review all content on the 
public website
•	  Content inventory drawn up and 
appropriate follow-up action taken
•	 Web resources revised for each 
area, and unit, and integrated into 
a new common module 
9.3.2. Increase interactivity and 
targeted approach of the website
9.3.2.1. Develop products with 
increased level of interactivity
•	  New, more interactive products 
launched (e.g. Topic-based 
‘spotlights’ produced as part of 
Annual report package, integrated 
responses profiles)  
9.3.2.2. Improve findability of 
information
•	  More possibilities for users to 
interact with information 
9.3.3. Introduce new quality 
assurance system for web content
9.3.3.1. Finalise web governance 
strategy
•	 Web governance strategy 
prepared, endorsed internally and 
implemented 
9.3.3.2. Implement new quality 
assurance measures
•	  Improved workflows for content 
sign-off, ensuring consistent 
approach for publishing content
•	 Quality threshold for various 
categories of information defined
9.3.4. Install new content management 
tool and migrate content
9.3.4.1. Select and tailor new content 
management tool 
•	  Efficient and flexible tool that better 
meets agency’s needs 
9.3.4.2. Select, migrate and enhance 
content
•	  Relevant content migrated
•	 Improved linking and findability of 
content
Specific objective 9.4: Enhance the EMCDDA’s reputation and recognition as the European central reference 
point for drugs information 
Priority interventions Planned activities Expected outputs/results
9.4.1. Organise European drugs 
conference in 2015 
9.4.1.1. Develop concept for 
conference 
•	  Clear concept and milestones 
available
9.4.2. Ensuring visibility of EMCDDA 
across multiple communication 
platforms
9.4.2.1. Organise weekly events 
planning meetings to ensure 
coordinated communication on key 
events and products
•	  Constant feed of news on EMCDDA 
activities and results  
9.4.2.2. Participate in exhibitions and 
events
•	  Awareness raising and positioning 
of EMCDDA’s work results and 
scientific expertise
9.4.2.3. Co-organise launch of EU 
drug markets report with Europol
•	  Report successfully launched across 
multiple communication platforms 
9.4.2.4. Organise exhibitions and 
events 
•	  The ‘Testing the waters’ conference 
organised 
•	  International drugs day event  
9.4.2.5. Organise Annual report 
launch 
•	  Report successfully launched across 
multiple communication platforms
9.4.2.6. Service meetings and 
conferences of scientific staff
•	  Ongoing support to scientific staff 
to EMCDDA visibility in technical 
activities
9.4.2.7. Prepare communication 
tools to promote the EMCDDA´s 
achievements within a broader 
audience
•	 ‘2012: a year in review’ prepared 
(based on the 2012 EMCDDA 
General report of activities) and 
published  
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Priority interventions Planned activities Expected outputs/results
9.4.2.8. Organise visits of external 
partners to EMCDDA
•	  Dissemination of knowledge and 
experience, increased visibility of 
EMCDDA among academic, policy 
and professional audiences
9.4.3. Continue to build sound 
contacts and relations with journalists 
and provide media-friendly information 
with clearly defined messages
9.4.3.1. Further develop contacts and 
relations with journalists
•	 Interviews set up, catalogue of 
journalist groups further developed
9.4.3.2. Provide media-friendly 
information
•	  High-quality press products in 
accessible formats, including video 
footage
9.4.3.3. Assess impact through 
monitoring and press reviews
•	  Clear view of return on investment 
from media activities through 
detailed press reviews and analyses
9.4.3.4. Organise training for 
EMCDDA staff and Reitox network
•	  Training organised, staff provided 
with improved communication skills
9.4.4. Public information service 9.4.4.1. Operate enquiry-answering 
service, produce website FAQs and 
other information
•	  Efficient public information desk 
operates in line with guidelines set 
by the European Ombudsman
9.4.5. Library and documentation 
services
9.4.5.1. Provide reliable and 
efficient information, library and 
documentation services supporting the 
research needs of the scientific staff
•	  Information bulletins published at 
regular intervals; ad hoc alerts 
distributed on an individual basis; 
literature searching; management 
of library services
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II.10. Governance, management and 
networks
Overview
The year 2013, the first within the 2013–15 strategy 
is important for setting the scene for governance 
and management work in the medium term. Also, 
the third external evaluation of the agency was 
completed in 2012 and the recommendations arising 
from this exercise will begin to be implemented. 
In the area of governance, the core objective 
in 2013 is to continue to provide the essential 
direction, resources and structure needed to ensure 
that the agency performs the tasks set out in its 
recast regulation and that it achieves its objectives. 
In order to accomplish this important goal, ongoing 
support will be provided to the Management Board 
(the governing body of the agency) in carrying out 
its mandate. This will include ongoing contact with 
the Board members, organisation of the statutory 
meetings and preparation of the documents to 
support their work. As is the case every year, 
two meetings of the Management Board will be 
organised, in July and in December. In addition, 
four meetings of the Executive Committee and four 
meetings of the Budget Committee will be held 
during the year to support the preparatory work.
The scientific work of the agency will continue to 
be guided by its Scientific Committee, which is the 
guardian of the EMCDDA’s scientific excellence. The 
Committee’s involvement in the planning process, 
the regular feedback provided to units and scientific 
staff, their input as peer reviewers and their advice 
throughout the year are central for the agency’s 
quality of work. As is the case every year, two 
statutory meetings of the Scientific Committee will 
be organised in 2013, in May and November. 
Giving the increasing need to prioritise activities 
in the context of the foreseen resources constraints, 
the Scientific Committee will further support the 
EMCDDA in this process, by helping to develop, 
together with the staff of the Centre, a transparent 
and structured mechanism for priority setting. 
The topic will be developed during the Scientific 
Committee meeting in May. In addition, as the 
current Scientific Committee’s mandate will expire in 
2014, preparatory work for the renewal procedure 
will be carried out in 2013, in line with the existing 
rules and procedures.
In order to successfully implement the strategic 
decisions adopted by the Management Board, 
further ensuring strong leadership and management 
practices is a core objective in 2013. Given the 
foreseeable budget constraints, it is becoming 
increasingly challenging for the agency to match 
its growing workload and new tasks with existing 
resources. Therefore, throughout the year, focus will 
be placed on achieving efficiency gains and further 
rationalising use of resources, while ensuring the 
high quality of our work. Achieving efficiency gains 
is one of the top-level commitments 2013–15 and 
is in line with the recommendations from the recent 
external evaluation exercise. This involves ongoing 
analysis of working processes and outcomes, in 
light of the resources they consume. The assessment 
of internal processes started in 2012 will be 
now completed and concrete measures to further 
rationalise use of resources will be proposed and 
started to be implemented.
Existing internal coordination efforts will be pursued 
and improved and all major issues relating to the 
implementation of core activities, timely achievement 
of results and effective delivery of outputs will 
continue to be closely discussed and monitored, 
mainly through the regular monthly meetings 
between the Director and the Heads of unit. These 
will also benefit from the preparatory work carried 
out in the Coordination Group meetings that are held 
twice a month.
In addition, decision-making processes will be 
supported through the provision of more operational 
and financial information — a result of improved 
planning, monitoring and reporting in the two related 
areas (see also Main area 11 — Administration: 
supporting core business). To this end, in line with 
developments taking place across all EU institutions 
and agencies, the strategic planning function of 
the agency will increase its contribution to the 
management decision-making process by providing 
more reliable and timely information on progress 
of activities and level of achievement of results. In 
order to fulfil this need, the main objective for the 
next three years in this area will be the setting up of 
a new performance management system. In 2013, 
the features of the system will be defined, including 
the IT tool to support its functioning. Conceptual work 
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for the development of performance indicators will 
be conducted, in close collaboration with the internal 
actors concerned, and also making use of best 
practices implemented at EU level.
In the area of internal control system and risk 
management, an ongoing task will be to maintain 
an updated repository of the state of compliance 
with the EMCDDA Internal Control Standards 
(ICS) for effective management and control. This 
effort will be combined with regular updates of the 
central risk register introduced in 2010. Setting 
up the business continuity plan will be a priority, 
especially in the areas supporting the agency’s 
core business. The thorough verification of financial 
transactions will continue, to ensure that they 
are carried out in accordance with the relevant 
regulatory requirements, including sound financial 
management.
A review of the document management processes 
and procedures will be conducted, to make sure 
that they are secure, efficient and comply with the 
applicable legislation (ICS no. 11).
Other highlights for this main area include the 
organisation in February of the first 2013 biannual 
meeting of the EU data protection officers (DPOs), 
with the participation of the EU data protection 
supervisor and DPOs from other EU agencies. 
Goal 2013–15: The EMCDDA attains good performance in carrying out the tasks set out in its recast 
Regulation and achievement of its objectives. This will be accomplished through good governance and 
efficient management and leadership, supported by enhanced planning, monitoring and reporting and an 
effective internal control and risk management system.
Specific objective 10.1: Ensure good governance to provide the strategic guidance and direction for the work 
of the EMCDDA 
Priority interventions Planned activities Expected outputs/results
10.1.1. Implement strategic decision-
making process at the level of the 
Management Board
10.1.1.1. Coordinate, prepare and 
organise follow-up of the meetings and 
decisions of the Management Board, 
of the Executive Committee and of the 
Budget Committee
•	  Two Management Board meetings, 
four Executive Committee meetings 
and four Budget Committee 
meetings organised and members 
provided with all the necessary 
documents and support to perform 
their duties
•	  2014 work programme, 2014 
budget, 2015 preliminary draft 
budget (PDB) and other statutory 
decisions adopted 
10.1.2. Provision of support and 
guidance by the Scientific Committee, 
to further enhance the scientific quality 
of the EMCDDA’s work
10.1.2.1. Coordinate, prepare and 
organise the meetings of the Scientific 
Committee and follow up on the 
conclusions and recommendations
•	  Two Scientific Committee meetings 
organised and members provided 
with all the necessary documents 
and support to perform their duties
10.1.2.2. Prepare renewal of the 
Scientific Committee
•	  Call for expressions of interest 
in membership in the EMCDDA 
Scientific Committee published and 
selection procedure finalised
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Specific objective 10.2: Ensure efficient management and leadership to support achievement of results and 
efficient use of resources 
Priority interventions Planned activities Expected outputs/results
10.2.1. Implement sound management 
organisation and practices
10.2.1.1. Perform top-level and 
middle-level managerial activities, 
organise regular Heads of Unit (HoU) 
and Coordination Group meetings and 
implement the decisions made 
•	  Further improved working structure, 
organisation and methods, to 
support efficient implementation of 
activities
•	  Annual work programmes 
implemented as planned and/or 
measures to improve performance 
taken, when necessary
•	  Heads of unit meetings organised 
and decision implemented
•	  Coordination group meetings 
organised, supporting the 
preparation of the HoU meetings 
10.2.1.2. Finalise assessment of 
internal processes to ensure that 
the agency’s resources are used 
in the most efficient, effective and 
economical manner
•	  Proposal to rationalise use of 
resources and improve performance 
prepared and endorsed internally 
and implementation of concrete 
measures started
10.2.1.3. Review processes and 
procedures for document management 
•	  Processes and procedures for 
document management reviewed 
and EMCDDA policy developed
10.2.1.4. Ensure compliance with the 
data protection rules applicable to EU 
bodies, Regulation (EC) 45/2001
•	  Data protection rules applicable 
to EU bodies (Regulation (EC) 
45/2001) observed in all 
EMCDDA activities
•	  DPO activities report prepared and 
disseminated internally
•	 First 2013 bi-annual meeting of 
the EU DPO Network meeting 
organised by the EMCDDA 
Specific objective 10.3: Improve and implement the agency’s strategic planning and programming cycle 
processes, to support timely delivery of results and sound decision-making concerning allocation of resources 
and actions to be taken to enhance performance 
Priority interventions Planned activities Expected outputs/results
10.3.1. Design and put in place an 
integrated performance measurement 
system to allow EMCDDA to better 
track progress of its achievements and 
detect implementation challenges in a 
timely way
10.3.1.1. Set up the performance 
measurement system
•	  Monitoring system designed
•	  Performance indicators defined for 
the main areas of work
10.3.2. Prepare the documents 
required by the strategic planning and 
programming cycle
10.3.2.1. Prepare the 2012 General 
report of activities
•	  2012 General report of activities 
published online by 15 June
10.3.2.2. Prepare the end-term 
monitoring report of the 2010–12 
EMCDDA strategy and work 
programme
•	  2010–12 strategy and work 
programme end-term monitoring 
report presented to the 
Management Board 
10.3.2.3. Develop the 2014 annual 
work programme
•	 2014 annual work programme 
submitted to the Management 
Board for adoption 
10.3.2.4. Prepare and conduct the 
2013 mid-year monitoring exercise
•	  Mid-year monitoring report 
prepared and used to support 
internal decision-making and 
planning
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Specific objective 10.4: Ensure effective internal control and risk management system
Priority interventions Planned activities Expected outputs/results
10.4.1. Implement sound internal 
control system
10.4.1.1. Verify thoroughly the 
financial transactions, notably as 
regards legality and regularity of 
operations, ensuring that they are 
made in accordance with the relevant 
regulatory requirements, including 
sound financial management 
•	  Ex-ante verification of all financial 
operations and corrections made 
where necessary
•	  Recording of exceptions, 
particularly in cases of breaches of 
financial rules
•	 Advice on best practices, notably 
as regards cost-effectiveness of 
operations, provided to internal 
actors 
10.4.1.2. Regularly update 
the repository on the state of 
implementation of the 16 EMCDDA 
Internal Control Standards (ICS) for 
effective management and control
•	  Regular assessment of the quality 
of the EMCDDA internal control 
systems to support risk managers 
on areas requiring risk-mitigating 
measures and/or upgrades of the 
key controls set in place
10.4.1.3. Regularly update the central 
and sector risk registers as required 
under ICS 6
•	  Identification and assessment of 
risks posed to EMCDDA activities 
and timely setting up of action 
plans to mitigate those risks 
10.4.1.4. Liaise effectively with 
the EMCDDA Internal Auditor 
(Internal Audit Service of the EC, 
IAS) with a view to taking stock of 
recommendations arising from audits 
in areas of strategic importance
•	  Proper implementation of 
recommendations addressed by the 
IAS to the EMCDDA in accordance 
with suitably designed action 
plans, leading to improvements 
in the internal controls object of 
recommendations 
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Reitox network
The work to coordinate the Reitox network will 
focus on three main priorities and challenges: (1) 
providing support for the implementation of decisions 
linked to the systemic review, starting with the 
launch of the agency’s new Annual report and the 
development of a quality assurance strategy, and 
by providing full support to the revision of reporting 
instruments; (2) moving forward the implementation 
of the Reitox development strategy with priority given 
to the added value of the work of NFPs at EU and 
national levels through the follow-up of the ‘Reitox 
focus groups’ initiative; and (3) starting to develop, 
in consultation with the Reitox NFPs, a reference 
model for the accreditation of the NFPs, in line with 
the recommendations of IAS and Court of Auditors.
Specific objective 10.5: Ensure that the Reitox network is efficiently managed and structured to meet future 
needs and requirements
Priority interventions Planned activities Expected outputs/results
10.5.1. Agree the annual reporting 
package and necessary developments 
to the overall reporting framework
10.5.1.1. Organise the Reitox Heads 
of focal point meetings
•	  Two Heads of focal points meetings 
organised, in May and November
•	  Meeting documents, presentations 
and results available online
10.5.1.2. Present to and agree with 
the Reitox NFPs the guidelines for 
national reporting
•	  New guidelines adopted at the 
Heads of focal points meeting in 
November 
10.5.1.3. Prepare and support 
the revision process of reporting 
instruments, in liaison with the 
Scientific Division
•	  Preparatory documents for each 
instrument to be revised in 2013 
presented at the Reitox May 
meeting
•	  First comprehensive proposals 
presented at Reitox technical 
meeting of September/October
•	  Full package adopted at November 
Reitox meeting and integrated in 
the guidelines for reporting 2014
10.5.1.4. Organise the systematic 
consultation of NFPs for draft 
guidelines and for the periodical 
revision of tools before adoption at the 
Reitox meeting of November
•	  Reitox technical meeting organised 
in September/October for analysis 
and discussion of first draft 
documents and agreement on way 
forward to prepare adoption at the 
November Reitox meeting 
10.5.2. Strengthen the Reitox network 
at national level as a high-quality 
provider of information
10.5.2.1. Provide on-site 
institutional support, in line with the 
recommendations formulated in the 
quality reports
•	  Institutional visits organised to the 
countries, as needed, and based 
on available resources 
10.5.2.2. Support NFPs in conducting 
the focus groups with harm reduction 
service providers at national level
•	  Work plan for developing the 
added value of NFPs in the area of 
‘demand reduction, interventions 
and solutions’ at national level, 
both for data collection and for 
knowledge dissemination, prepared 
and agreed with the NFPs
10.5.2.3. Organise a Reitox Academy 
on misuse of medicines in the context 
of polydrug use
•	  30 NFPs trained
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Priority interventions Planned activities Expected outputs/results
10.5.2.4. Define a reference 
framework in consultation with 
NFPs for the development of an 
accreditation process
•	  Technical meeting organised 
•	  One draft proposal presented at 
the Reitox Technical meeting of 
September/October 2013
•	  General proposal presented for 
adoption at the November meeting
10.5.3. Develop an integrated 
approach to capacity development 
and to quality assurance
10.5.3.1. Support organisation 
of national and regional Reitox 
Academies upon request and needs 
from the NFPs
•	  Two national or regional Reitox 
Academies on 5 KIs and two Reitox 
Academies on responses organised 
for EMCDDA Member States, upon 
request
10.5.4. Strengthen the management 
and organisational processes and 
procedures
10.5.4.1. Support NFPs in the 
management and implementation of 
their yearly grant agreement
•	  27 Grant Agreements signed and 
implemented for the whole year, 
and one first Grant Agreement 
signed and implemented with 
Croatia for the second half of the 
year
•	  A Reitox academy on grant 
management for at least ten 
representatives from selected EU 
Member States organised by mid-
2013 
•	  NFPs better trained in EU financial 
regulation and consequent grant 
implementation 
•	  3 on-site audit visits and training 
support
10.5.4.2. Implement further steps 
to ensure that the management 
information system (HERMES) 
developed for the technical 
cooperation activities and 
management of grants is fully 
operational
•	  HERMES reports used to track the 
progress of implementation of the 
work programme
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II.11. Administration: supporting core 
business
Overview
The EMCDDA administration function is expected to 
contribute significantly to fulfilling one of the top-level 
commitments for the 2013–15 programming period, 
namely the commitment to efficiency and deriving 
maximum value from activities and investments. At 
the same time, through providing quality support 
services to core business, it will make an important 
contribution to achieving the other two top-level 
commitments that will drive the work of the EMCDDA 
over the next three years. Therefore, enhancing 
efficiency, further developing sound management of 
available resources and providing service-oriented 
administrative support to the EMCDDA’s operations 
will represent main priorities across all the activities 
within the administration area.
In the financial management area, the focus will 
be on aligning the EMCDDA’s financial rules and 
processes to the revised EU financial regulations 
and enhancing efficiency of relevant transactions, 
with special attention to procurements and staff 
missions. Aligning internal financial rules and 
procedures with the revised EU-applicable legislation 
will require revision of the current rules, together 
with updating of the internal procedures, manuals 
and templates and the provision of training to the 
internal actors involved. At the same time, further 
improving effectiveness and efficiency of financial 
transactions (payment process) is envisaged. This 
will be achieved by means of, among others, the 
2013 annual assessment of the EMCDDA financial 
and administrative implementation of the budget 
and the work programme, followed by a proposal 
of measures to improve budget execution and the 
use of the earmarked resources. Implementation of 
digitalised tools and processes, such as electronic 
workflow for relevant financial transactions and a 
new ICT-based tool for staff missions’ management 
will also contribute to this objective. A key 
intervention will be to rationalise and optimise 
tendering processes. This will involve defining and 
implementing the 2013 annual procurement plan, 
as an integral part of the agency’s work programme 
implementation, as well as providing support to the 
staff concerned. As additional means to rationalise 
procurements, the increased use of framework 
contracts, long-term contracts and multiannual calls 
for tenders will be promoted, and training will be 
provided to project managers in the core business 
area, in order to make use of these options whenever 
possible. Furthermore, with a view to making use 
of common facilities and services and achieving 
economies of scale, we will continue to develop 
synergies with other EU bodies in general and with 
the ones based in Lisbon in particular.
Another important objective will be to ensure and 
further enhance effectiveness and efficiency in 
budget execution and management. This will involve 
timely preparation and use of budget planning and 
management tools (such as draft budget, amending 
budgets, budget transfers) in line with the EMCDDA 
priorities. Further development of the EMCDDA 
activity-based management (ABM) and activity-based 
budgeting (ABB) system, as well as implementation 
of improved reporting tools, will contribute to 
reaching this objective. One of the highlights for 
2013 will be the contribution to the needs definition 
and resources required for the development of an IT 
tool to support integrated operational and financial 
planning within the new performance management 
system, to be put in place by the end of 2015 (see 
also Main area 10: Governance, management and 
networks).
In the accounting area, the objective will be to 
enhance the quality of the EMCDDA accounting 
management and reporting, through developing 
accounting of assets and further clarifying the 
conditions and requirements for effective accounting 
management. This will involve assessment of the 
solutions/tools to improve accounting of the agency’s 
assets and better integration with existing SAP-based 
accounting system and implementation. The Charter 
of the EMCDDA Accounting Officer will be also 
adopted.
In the human resources (HR) management area a 
main priority will be to align the EMCDDA’s HR 
processes and policies with the forthcoming reform 
of the EU staff regulations. This will require, among 
other things, preparing the agency’s implementing 
rules and informing staff on the main aspects of 
the reform, concerning rights/entitlements and 
obligations. Another priority will be to further 
digitalise the HR management processes. This will 
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continue the projects developed in previous years 
and will contribute to increased efficiency and 
transparency. An important element for 2013 will be 
the follow-up to the staff opinion survey conducted 
in 2012. Based on the results of the study, career 
development-related policies might need to be 
reviewed. Further developing the capacity of the 
agency’s staff through provision of training will 
be another key priority. The training plan will be 
updated during the year and a new system for 
assessing the effectiveness, quality and added value 
of the training will be implemented.
In the area of infrastructure and logistics, 
measures to ensure and develop effective and 
efficient management of the EMCDDA’s premises, 
infrastructures and relevant services will be 
implemented. This will involve optimising the use of 
the available facilities, equipment and infrastructure, 
contributing to reducing utility costs and, more 
importantly, ensuring a healthy working environment 
for the agency’s staff. Moreover, the efforts to find a 
suitable solution for renting or selling the premises 
which are currently not occupied will be further 
pursued. A key priority will be to ensure safety 
at work, sound environmental management and 
security in the buildings. This will be done by means 
of, among others, reviewing the Annual security 
risk assessment of the EMCDDA, in order to identify 
and evaluate risks, foresee new developments and 
propose mitigation measures to reduce impact and 
likeliness. Also, the Business Continuity Plan (BCP) 
will be further developed and an Environmental 
Management System (EMS) will be put in place. 
Regular training of staff and Wardens on evacuation 
procedures will be carried out. 
Goal 2013–15: Ensure effective and efficient allocation and management of financial and human resources 
and assets, through further rationalising internal processes, while developing the quality of services and 
support provided.
 
 
Financial and budget management, and accounting
Specific objective 11.1: Enhance effectiveness and efficiency in the execution of the budget and in the 
management and accounting of financial resources
Priority interventions Planned activities Expected outputs/results
11.1.1. Align the EMCDDA’s 
financial rules with the revised EU 
financial regulation and ensure their 
implementation
11.1.1.1. Adapt work processes 
in line with the revised EU financial 
regulation 
•	  Updated procedures, manuals and 
templates in place 
11.1.1.2. Train relevant staff to apply 
the revised financial rules 
•	  Financial and contractual support 
officers trained to ensure correct 
implementation of the revised rules
•	  Financial actors trained to ensure 
correct implementation of the 
revised rules
11.1.2. Further improve effectiveness 
and efficiency of financial transactions 
(payment process) and procurement 
processes
11.1.2.1. Conduct annual assessment 
of EMCDDA’s financial and 
administrative implementation of the 
budget and work programme
•	  Further measures to improve 
budget execution and use of work 
programme resources 
11.1.2.2. Implement digitalised tools 
and processes (based on available 
resources) 
•	  Electronic workflow procedures 
conceptualised (e.g. pilot phase for 
commercial invoices)
•	  ICT-based tool for staff missions 
management developed and 
piloted 
11.1.2.3. Revise travel forms to 
reduce the number of transactions for 
each mission
•	  Improved average timeframe for 
payments (as compared with 2011)
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Priority interventions Planned activities Expected outputs/results
11.1.2.4. Implement measures to 
rationalise and optimise tendering 
processes, resulting in timely and 
successful execution of procurements
•	  2013 annual procurement plan in 
place
•	  Training provided to all scientific 
project managers
11.1.3. Ensure effective and timely 
preparation and use of budget 
planning and management tools in 
line with EMCDDA priorities and 
constraints and in accordance with 
ABM/ABB principles
11.1.3.1. Prepare and submit 
for approval the budget-planning 
instruments in a timely manner
•	  EMCDDA 2014 draft budget (DB) 
and 2015 preliminary draft budget 
(PDB) adopted
11.1.3.2. Prepare forecast analyses 
on impact of policy and operational 
issues on the budget, to support 
decision-making at management level
•	  Budgetary scenarios and progress 
reports submitted in appropriate 
format
11.1.3.3. Facilitate effective use of the 
2013 budget
•	  High rate of budget execution
11.1.3.4. Further develop activity-
based budgeting approach
•	  Options for further development 
identified and possible solutions 
chosen
11.1.4. Develop customised reporting 
on budget execution
11.1.4.1. Prepare budgetary reports, 
including visualisation of main 
budgetary trends
•	  Regular statistical reports and 
customised reports on budget 
execution
11.1.4.2. Build new reporting tool to 
further match/liaise budget execution 
and accounting
•	  Increasing internal control between 
budget execution and accounting
11.1.5. Improve the accounting of 
EMCDDA assets, and further define 
the conditions and requirements for 
the function of accounting officer at 
the EMCDDA according to applicable 
financial rules
11.1.5.1. Assess and implement 
solutions/tools to improve accounting 
of EMCDDA assets and achieve better 
integration with existing SAP-based 
accounting system
•	  Optimal solution identified
11.1.5.2. Develop charter of the 
EMCDDA accounting officer including 
clear definition of requirements, 
conditions and responsibilities for the 
function of accounting officer
•	  Charter of the EMCDDA accounting 
officer adopted
Human resources management
Specific objective 11.2: Maximise efficiency and effectiveness of HR management at the EMCDDA
Priority interventions Planned activities Expected outputs/results
11.2.1. Align EMCDDA HR processes 
and policies with the forthcoming 
reform of the EU staff regulations
11.2.1.1. Revise HR processes and 
policies in line with the new rules 
•	  Revised rights and entitlements
•	 Employment contracts of temporary 
agents (TA) amended and signed
•	 New recruitment templates in place 
11.2.1.2. Organise information 
sessions to staff
•	  Information sessions on the main 
aspects of the reform organised 
and staff properly informed of 
rights/entitlements and obligations
11.2.2. Further digitalise HR 
management processes through the 
development of ICT tools to increase 
their efficiency and effectiveness
11.2.2.1. Analyse and implement 
options to maximise use of the HR 
database
•	  Solutions to further improve use 
of the HR database identified and 
implemented
•	 Integration of existing staff 
documents into the database to the 
best possible extent 
11.2.2.2. Develop ICT solution for 
leave management, integrated with the 
HR database
•	  Technical specifications developed 
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Priority interventions Planned activities Expected outputs/results
11.2.3. Follow up the outcome of the 
2012 staff opinion survey
11.2.3.1. Develop action plan to 
follow up the survey
•	 Action plan developed and 
approved by the Director, as 
required 
11.2.3.2. Develop career paths by 
relying on the concept of ‘job families’ 
to define a clear framework for career 
development
•	  Feasibility study for definition of 
career path/job families at the 
EMCDDA
11.2.4. Further develop EMCDDA 
working and production capacity by 
maximising training opportunities for 
EMCDDA staff
11.2.4.1. Develop/update the training 
plan as required to match working 
priorities and needs, and the available 
resources 
•	  Training plan in line with EMCDDA 
working priorities
•	 New system for assessing training 
effectiveness, quality and added 
value introduced 
11.2.4.2. Organise further training 
activities to improve managerial 
capacity 
•	  Training/coaching sessions 
provided to middle managers
Infrastructure and logistics
Specific objective 11.3: Ensuring a healthy working environment and further reduce utility costs by optimising 
the use of the available facilities, equipment and infrastructure
Priority interventions Planned activities Expected outputs/results
11.3.1. Ensure safety at work, sound 
environmental management and 
security in the buildings, including 
reducing utility costs and promoting 
use of renewable energy
11.3.1.1. Review ‘Annual security 
risk assessment of the EMCDDA to 
identify and evaluate risks, foresee 
new developments and propose 
mitigation measures to reduce impact 
and likeliness  
•	 Business continuity plan developed
•	 Share best practice by participation 
in Security symposium and BCP 
seminar
•	 Risk assessment prepared   
11.3.1.2. Develop, put in place 
and promote an Environmental 
Management System (EMS) within the 
Agency
•	  EMS in place
•	 Contribution to the Greening 
network meeting
11.3.1.3. Conduct training of 
staff and wardens on evacuation 
procedures 
•	 Evacuation exercise carried out 
successfully
11.3.1.4. Implement measures to 
rationalise cost for utilities and service 
contracts
•	  Reduction in utility costs as 
compared with 2012 benchmark 
11.3.2. Provide a suitable working 
environment and related services, and 
improve efficiency and effectiveness 
through promoting a customer-
orientated approach
11.3.2.1. Implement appropriate 
management of the premises and 
further improve access to logistics 
services, to provide optimal working 
conditions for EMCDDA staff 
•	 Health and safety risks identified 
and addressed
•	 Increased use of e-support tools 
for service requests through the 
Infrastructure and logistics intranet 
(in comparison to 2011) 
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II.12. Information and communication 
technology (ICT)
Overview
ICT programmes and services are planned to support 
the agency’s core developmental objectives, and 
to guarantee the smooth operation of all running 
services, including office running support, corporate 
application hosting and management of the data 
centre.
In times of rapid technological development and 
increasing expectations from both external and 
internal agency stakeholders, developing ICT 
governance is key to helping the agency implement 
its work programme and achieve its mission.
Three overarching priorities were identified for the 
ICT area in the 2013–15 work programme and they 
guide the work in 2013. The main priorities are 
overseen by the agency’s ICT Steering Committee, 
a core instrument of ICT governance, engaging the 
executive level of EMCDDA management in project 
(and activities) portfolio management.
The first priority intervention, to develop and 
maintain instruments for supporting core business, 
supports the pillar work processes of the agency, 
including data collection and analysis, development 
and dissemination of EMCDDA products, and 
governance processes. Within this intervention, the 
following priorities were identified and defined by 
the ICT Steering Committee: (1) web presence review 
programme; (2) support to the annual drugs data 
collection and analysis; and (3) collaborative content 
management.
The second priority intervention aims to implement 
a ‘Business and information architecture 
management’ programme. In its stepwise execution, 
it encompasses business/IT architecture development 
and its technical implementation. The main objective 
here will be to ensure well-planned maintenance and 
evolution of the EMCDDA’s technical environment. 
In practical terms, this will lead to the planned 
replacement of central server components, network 
equipment and standard software. For 2013, on 
the technical side this mainly means to start the 
gradual replacement of the corporate T2000 servers 
that are reaching the end of their life, and making 
operating system (OS) upgrades to servers and end 
users’ workstations. Conceptually, the data and ETL 
(extract transform load) architecture that supports the 
prioritised core business areas must be reviewed, 
and the first step towards defining a formal business 
architecture must be taken. A topic of special 
importance with regard to risk and compliance 
management is the development of the architectural 
pattern to support business continuity requirements.
The third priority intervention, to implement a 
‘Technical services management’ programme, 
includes ongoing service management. This 
encompasses most of the effort and resources 
dedicated to business-as-usual services; therefore, the 
majority of resources are earmarked for this area. 
Formal procedures to ensure service availability and 
to leverage the advantages associated with any 
modifications will be promoted. Developing the role 
of the ICT Steering Committee, implementing best 
practice, and abiding by the recommendations of an 
IAS risk assessment and the EMCDDA risk register, is 
also part of this intervention.
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Goal 2013–15: Support the agency in achieving its objectives by providing high-quality and efficient ICT 
services.
 
Specific objective 12.1: Develop and maintain ICT solutions and tools to support the EMCDDA’s work, while 
applying best practices and standards of ICT governance, planning and service management
Priority interventions Planned activities Expected outputs/results
12.1.1. Develop and maintain 
instruments for supporting core 
business
12.1.1.1. Develop and maintain 
infrastructure for the annual drugs data 
collection and analysis, reflecting the 
evolution of the drugs data set and its 
protocols
•	  Fonte online data collection system 
set up for annual run; application 
updates performed during the year, 
as required
•	 Analytical drugs database updated 
for 2013  
12.1.1.2. Develop new best practice 
portal information system
•	 Roadmap report
•	 EDDRA review (analysis report)
12.1.1.3. Provide support for business 
review of the ‘monitoring the Internet’ 
programme
•	  Roadmap report 
12.1.1.4. Support new information 
system in the area of EDND
•	  Roadmap report
•	 Functional analysis conducted and 
requirements identified
•	 Project Match-It, pilot version of 
the supporting application made 
available 
12.1.1.5. Support the development 
of a content lifecycle management 
approach
•	 Roadmap for the development of 
a collaborative content editing 
platform 
12.1.1.6. Develop strategy and 
roadmap for implementing a dynamic 
web presence capability
•	  Roadmap report
12.1.1.7. Support new web content 
management and visualisation 
platform
•	  Roadmap report
•	 Functional analysis conducted and 
requirements identified
•	 Market solutions survey report
•	 Design report
•	 Tendering process (phase 1) 
12.1.1.8. Support business 
requirements in the corporate and 
administrative areas (see also Main 
areas 10 and 11) 
•	  Technical solutions for the IT tool 
supporting the new performance 
management system identified 
(support as required)
•	 Roadmap (continued) and roadmap 
implementation (phase 1 or 
small solution) for the missions 
management IT tool
•	 Electronic workflow procedures 
conceptualised
•	 Strategy for document management 
adopted and launched
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Priority interventions Planned activities Expected outputs/results
12.1.2. Implement ‘Business and 
information architecture management’ 
programme
12.1.2.1. Set up ‘Business 
architecture’ programme
•	 Corporate architecture reviewed
•	 Mission/vision for business 
architecture developed
•	 Business requirements defined
12.1.2.2. Develop information, 
application and data architecture, 
development process
•	  Software configuration and change 
management architecture reviewed
•	  Business continuity architecture 
developed
•	  Data architecture reviewed in 
light of changes in data and web 
publications
•	 Security architecture reviewed
•	 ETL architecture reviewed to 
support drugs data analysis and 
dissemination of results
12.1.3. Implement ‘Technical services 
management’ programme
12.1.3.1. Implement technical 
architecture development process
•	  Software licences maintained; 
servers and infrastructure functional
•	  Corporate business architecture 
reviewed
•	  Corporate servers replaced
•	  Upgrades for corporate server; 
operating system (OS); corporate 
database; client OS; collaboration 
platform
•	  Productivity software update 
finalised
•	  Meeting room equipment: 
acquisition and installation phase
•	  New laptops procured and 
installed
12.1.3.2. Develop project portfolio 
concept in coordination with the ICT 
Steering Committee
•	  Improved planning and 
management of ICT resources
12.1.3.3. Streamline ICT acquisition 
processes, using framework contracts 
and similar tools
•	  Procurement processes optimised 
through increased collaboration 
on specific subjects/dossiers 
with institutional networks, other 
agencies and European institutions
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Annex I: Potential risk factors
Risk factors
During 2012, in line with the approach already 
followed throughout 2010 and 2011, and in the 
framework of a more systematic risk identification 
and assessment exercise, the EMCDDA has identified 
potential risk factors that could affect its planned 
deliveries. A fully fledged central risk register was 
set up in 2010, which has benefited from successive 
updates since then. The table below is based on that 
register; it lists the main potential risks that could 
negatively impact on the expected outputs and 
compliance with the EMCDDA’s objectives for 2013. 
A brief assessment of the likelihood of occurrence 
and of potential impacts of the risks identified is 
also provided, along with a summary of the main 
mitigating measures already taken and planned to 
tackle risks identified (where applicable).
Risk factors identified for delivery of the 2013 work 
programme
Likelihood of risk and respective impact on the 2013 work 
programme
External risks with a direct link to specific fields of the annual work programme
1. Substantial change from 2013 onwards of the amounts 
granted by the EC to the EMCDDA (when compared with 
amounts granted over the 2010–12 period).
The 2013 work programme has been drawn up on the 
basis of the EMCDDA’s draft budget for 2013, which relies 
on an expected EC funding of EUR 15 550 000 (the same 
value as for 2012). Any reduction in this sum could require 
processes and outputs to be reviewed.
2. Supplementary specific requests from EU institutions 
to provide technical support for the implementation of 
EC programmes and actions, in particular as regards 
implementation of the Council Decision on new 
psychoactive substances.
An extensive number of core tasks in support of the EU 
institutions have been foreseen for 2013, particularly 
involving, but not limited to, provision of expertise and 
technical information in the framework of the EU drugs 
strategy, the Council Decision on new psychoactive 
substances, the second progress report for implementing 
the Council Recommendation of 18.6.2003, the drug 
policy dialogue, the monitoring of supply and supply 
reduction interventions and the EU Framework for minimum 
quality standards and benchmarks in drug demand 
reduction (EQUS).
However, additional requests from EU institutions to 
provide technical support for implementing actions and 
programmes could require priorities to be reviewed (7) 
or supplementary resources to be identified. Concerning, 
in particular, the implementation of the Council Decision 
on new psychoactive substances, and in view of the high 
number of psychoactive substances appearing over a 
short time period, a significant risk exists that multiple risk 
assessment exercises will be required on these, which 
would pose an additional burden on the work programme 
and budget resources available. 
3. Supplementary requests from Member States and third 
parties to provide expertise in specific domains.
The current level of requests can be accommodated in 
routine work, but a significant increase in demand for this 
type of expertise would need additional scientific resources 
dedicated to it and would need to be balanced against 
other priorities of the work programme (see footnote 7).
(7) The process for reviewing priorities is as follows: identify projects/meetings/studies/recruitments that can be delayed, downsized or 
cancelled and reassign resources appropriately.
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Risk factors identified for delivery of the 2013 work 
programme
Likelihood of risk and respective impact on the 2013 work 
programme
4.1. Lack of appropriate funding for National Focal Points 
(NFP) in the Member States, which might negatively impact 
on their capacity to comply with reporting obligations 
towards the EMCDDA. This risk could be compounded by 
insufficient funding for information collection in Member 
States as a whole, which in itself would curtail the NFP 
capability to provide reliable information to the EMCDDA.
All core monitoring activities could be affected, notably 
the review of developments in drugs use and responses in 
Europe.
However, the high political visibility of the drug 
phenomenon renders unlikely sizeable and widespread 
cuts in NFP financing and acts as a mitigating risk factor. 
In such an unfavourable scenario, priorities assigned to 
the NFP affected would have to be reviewed, in order to 
ensure availability of core information. Outsourcing by the 
EMCDDA of tasks to NFP staff could also be envisaged as 
a mitigating measure, should the necessary appropriations 
be available in the EMCDDA budget.
4.2. Lack of specific expertise in sensitive spots (such 
as prisons and hospitals) in Member States or of core 
information at the quality levels required for the production 
of certain products planned by the EMCDDA.
Core activities would not in principle be affected. 
However, the quality of certain publications (for instance, 
Monographs and Insights series) could suffer should this 
risk materialise.
The likelihood of occurrence and impact of this risk can be 
considered as medium, since it is in principle confined to 
Member States experiencing a less favourable economic 
situation.
Should this risk materialise, planning of publications 
would have to be adjusted in accordance with the quality 
of information and expertise available in the areas 
concerned; this would entail reallocation of planned 
publications to alternative products, where feasible.
5. Unauthorised use or misuse of EMCDDA products by 
external parties, notably for commercial or profit-making 
activities. Such abuses might entail reputation risks to the 
agency, notably if the contents of the original publications 
were to be modified, rendered incomplete or inaccurate 
and the EMCDDA be cited as the editorial source.
This risk materialised at the beginning of 2011, in that 
the copyrights of a number of EMCDDA publications have 
been violated. Although there is so far no evidence that the 
contents of its outputs have been substantially changed, the 
reputation risk remains since the agency does not have any 
control on the quality of products identifying it as the editor 
and sold illegally by a private company.
Since this practice has affected a wide range of EU 
institutions and agencies, the EC Publications Office has 
requested the publisher in question to cease these activities. 
This situation has, however, persisted throughout 2012, 
which might mean that the publisher is making profits 
on the basis of these abuses; the possibility of setting up 
controls for downloading our external products ought 
therefore to be assessed, while keeping in mind that they 
should be made available to audiences as widely as 
possible. A legal ‘class action’ against the publisher has 
been envisaged and would require coordination with EU 
institutions and agencies also affected by this unlawful 
practice.
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Risk factors identified for delivery of the 2013 work 
programme
Likelihood of risk and respective impact on the 2013 work 
programme
External events that might have an impact on the implementation of the annual work programme as a whole
6. Natural catastrophes: earthquakes (leading to possible 
tsunamis) or floods
The location of the EMCDDA facilities, bordering the Tagus 
river, raises a potential risk of being affected by any of 
these natural catastrophes.
The likely consequences of a major earthquake are hardly 
predictable and appropriate measures would have to 
be taken in order to deal with the resulting damages. 
The EMCDDA is presently located in an area of seismic 
activity. The likelihood of a tsunami comparable to the 
one that destroyed downtown Lisbon 255 years ago 
can be considered as very low, since it is clearly a rare 
phenomenon. A landslide of the building caused by 
earthquakes, although not very likely, cannot be ruled out.
As regards Tagus flooding, some information available 
(notably a report issued by Unisys in 2008) leads us to 
believe that the potential risk here is low. On the other 
hand, it is conceivable that a combination of heavy 
rain with Tagus high tides could cause flooding of the 
underground car park. Further mitigating measures to deal 
with this risk ought to be agreed with and taken by the 
Administration of the Port of Lisbon (APL), the entity that 
owns the Cais do Sodré building. A letter to this effect was 
sent to APL in November 2010, followed by a reminder in 
July 2012.
Furthermore, a very comprehensive insurance contract 
covering, inter alia, adverse effects from earthquakes, 
landslides and floods has been signed and would provide 
financial compensation should these events materialise.
7. Terrorist attacks The new facilities, as they are more visible than before, 
could, at least in theory, attract the attention of terrorist 
groups. The likelihood of such an event is considered as 
low, mostly because Portugal has no serious recent history 
of this kind of attack. Moreover, if the target of such actions 
were to be the EU institutions or the like, there are far more 
visible and emblematic institutions in Europe, a fact that 
should decrease the potential risk faced by the EMCDDA in 
this respect.
The insurance policy for the EMCDDA building covers, 
inter alia, this risk.
Internal risks
8.1 Information technology (IT) — governance risks, 
notably linked to:
a) suboptimal investment decisions in IT;
b) certain weaknesses in the management of IT projects;
c) insufficient licensing and assets management procedures
A vast number of mitigating measures to deal with these 
risks have been implemented, namely: (a) setting up 
of a register with a categorisation of ICT investments; 
development of a detailed report on ICT activities for 
2010 and 2011; setting up of a project catalogue for 
ICT; creation of an ICT Investments Steering Committee; 
implementation of a project portfolio management process; 
(b) participation of the EMCDDA in inter-institutional 
framework contracts; adoption of a ‘turn-key’ approach 
to projects; (c) implementation of the I-Desk M2009 
programme.
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Risk factors identified for delivery of the 2013 work 
programme
Likelihood of risk and respective impact on the 2013 work 
programme
A wide range of additional measures and actions is 
expected to reduce existing risks to tolerable levels until 
the end of 2013 at the latest: (a) to further improve 
documentation of procedures and appropriate guidelines 
leading to sound decisions on IT investments; (b) to further 
develop the work of the ICT Steering Committee in order to 
ensure coherence in investments with core business needs; 
definition and implementation of a project management 
and execution methodology; (c) to enhance planning and 
control of license and assets utilisation; to set up the ICT 
Services Catalogue allowing stakeholders’ needs for IT 
services to be better addressed.
8.2 IT — technical risks, notably linked to:
a) software configuration management problems resulting 
from not properly planned installations of software;
b) inconsistent application of patching procedures, 
compounded by insufficient documentation of interventions 
and systems updates;
c) difficulties in ensuring business continuity and swift 
recovery in cases of incidents or disasters, due to both 
governance-related and technical risks; and
d) security violations, due to some lack of adequate 
procedures in the IT area.
Most relevant mitigating measures have already been 
implemented, such as: (a) setting up of an automatic 
monitoring system to deal with installed configurations; 
implementation of technical tools addressing 
management of software configuration issues; conception 
of a ‘documentation tree’ as the basis for a future 
documentation set covering risk management, security 
and governance in IT; (b) ad hoc testing of potential 
consequences emerging from patching procedural 
weaknesses and systematic registration of interventions 
performed; setting up of a Definitive Software Library (DSL), 
indicating software versions in use and patches installed; 
(c) definition of standards for a Business Continuity Plan 
(BCP) of the EMCDDA as a whole; hosting of the agency 
portal in degraded mode at an alternate site; use of a 
framework contract for supporting business continuity; 
procurement of specialised assistance services in cases of 
disaster; documentation of key technical dependencies in 
ICT; and (d) installation of network management software 
combined with an update of the software version of 
Firewalls; introduction of modules for intrusion detection 
and prevention; increased protection against malware and 
virus threats.
Furthermore, a comprehensive set of measures has 
been foreseen in order to further reduce risk levels: (a) 
establishment of standard documentation on the technical 
infrastructure and procedures to follow in operations; (b) 
definition of specific guidelines for patching in servers; (c) 
finalisation of the work started in implementing the business 
continuity and disaster recovery plans; improvement of the 
documentation on dependencies amongst the components 
of the EMCDDA ICT infrastructure; development of 
Santa Apolónia as the service continuity support site; 
accomplishment of a fully fledged BCP; and (d) to contract 
and carry out telecom security-related services, as well as 
external audits on sensitive areas of the EMCDDA core 
business (e.g. CMA and Fonte).
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Risk factors identified for delivery of the 2013 work 
programme
Likelihood of risk and respective impact on the 2013 work 
programme
9. Unexpected departure of key members of staff Given the highly specialised and technical nature of 
much of the agency’s work, finding suitable replacements 
can be a time-consuming task. The EMCDDA 2010 
reorganisation of scientific units provided sounder back-
up arrangements for all staff concerned, whilst allowing a 
wider decentralisation of responsibilities in this key area. 
Investment in human resources ensures that arising needs 
can be acted upon with minimum delay in most cases. Job 
profiles have been designed with a view to recruiting staff 
for transversal tasks and facilitating sharing of knowledge 
and expertise within small working groups. Moreover, it 
has been planned to shorten the current delays for staff 
recruitment. A stable contracts policy with key staff, notably 
in scientific areas, has been pursued and ought to be 
reinforced.
Risk management
The worst-case scenario would be linked to a major 
earthquake leading to a tsunami. As hinted above, 
an emergency/salvage plan conceived to address 
the resulting damages would be needed. Even 
so, disruption of the EMCDDA’s activities would 
probably ensue, the respective duration being 
dependent on the severity of the catastrophe and on 
the promptness of the aid received from public and/
or private sources.
It is to be noted that a very comprehensive insurance 
contract covering, inter alia, adverse effects arising 
from earthquakes, landslides, floods and terrorist 
attacks has been in force since 2010 and would 
provide the necessary financial compensation should 
such events materialise. The responsibility for further 
measures aimed at mitigating the risk of floods at the 
building belongs to its owner, the APL, as stipulated 
under the leasing contract.
Regarding specifically the risks linked to the IT 
area, which have been subject to particularly close 
scrutiny, the main related consequences would 
be felt on business continuity and sound financial 
management, the latter to the extent that suboptimal 
investments in IT could ensue, in terms of both 
purchases made and value for money obtained 
thereby. It is to be noted, however, that extensive 
action has already been taken in these areas, 
particularly throughout the last two years; these, 
combined with those currently being implemented 
and planned for 2013, are expected to bring down 
these risks to tolerable levels by the end of 2013.
Apart from the situations mentioned in the 
paragraphs above, the main consequences that 
could arise from materialisation of the risks identified 
would sequentially be:
a) reduced activities in support of partners and for 
non-core tasks;
b) delay or postponement of necessary 
developmental work, support and capacity-building 
activities;
c) reduction in capacity for analytical work and 
transversal products;
d) reduction in the scope or quality of planned 
outputs.
Except for major catastrophes (notably tsunamis), 
should any of the above scenarios occur, a detailed 
assessment of their impact both in budgetary and 
operational terms would have to be conducted. The 
implications of this assessment would then need to 
be considered in terms of the overall priorities of the 
work programme.
In case of major catastrophes, further measures 
would of course be needed.
The EMCDDA has used and will further strengthen 
its internal capacity to prevent, manage and 
minimise the impact of the abovementioned risks. 
Further to the mitigating measures described 
above, it has improved the planning, monitoring, 
assessment and execution of its work programme 
and budget (activity planning and monitoring of 
work programmes have been assigned since 2010 
to the Director’s Office). Moreover, throughout 2012 
a close monitoring of the state of implementation of 
the EMCDDA Internal Control Standards has been 
conducted in the framework of the risk management 
(namely, assessment of internal control systems) 
exercise carried out at the agency.
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Annex II: Estimated allocation/use of the appropriations provided under the EMCDDA 
2013 budget for the implementation of the EMCDDA 2013 work programme
The amounts indicated in the table below are 
based on the EMCDDA’s budget for 2013 that the 
EMCDDA’s Management Board should adopt in 
December 2012. This budget relies on the following 
revenues:
•	 EUR 15 550 000,00 to be provided by the EC 
subsidy to the EMCDDA;
•	 EUR 405 853,44 to be provided by Norway for 
its participation in the EMCDDA;
•	 EUR 100 000,00 to be provided by Turkey for 
its 1st year of participation in the EMCDDA, by 
assuming that the relevant agreement will enter 
into force on 1st Jan 2013;
Furthermore the EMCDDA’s 2013 budget enters 
as assigned appropriations a financing of EUR 
350.000 from the IPA programme for the execution 
in 2013 of a project for technical assistance aimed 
at preparing IPA Beneficiaries for their participation 
in the EMCDDA (so called IPA 4 project – 2nd year 
of execution).
The tables below present the estimated allocation 
of the EMCDDA’s 2013 budget appropriations for 
the implementation of the EMCDDA’s 2013 work 
programme.
A. Monitoring and reporting on the drugs problem in Europe (vertical operations)
WP objectives and 
activities
Main 
actors for 
implemen-
tation
Allocated human resources (fte/
year)(1)
Allocated budget resources — Non assigned 
appropriations (€)
O TA CA SNE Total 
HR
For direct cost of 
operations (2)
For indirect cost 
of operations (3)
Total budget
Data collection, analysis 
and quality assurance
EPI + IBS + 
RTX
0.5 2.5 3.5 0 6.5 457 447.80 641 893.64 1 099 341.45
Monitoring and 
understanding drug 
use and problems: 
key indicators and 
epidemiology
EPI 0.5 5 1 0 6.5 565 840.48 653 089.57 1 218 930.04
Monitoring demand 
reduction responses 
applied to drug-related 
problems
IBS 2 4.7 0.5 0 7.2 707 995.58 714 859.92 1 422 855.50
Monitoring drug supply 
and supply reduction 
interventions
SAT 0 2.5 1 1 4.5 381 623.64 326 866.56 708 490.20
Monitoring new trends 
and developments and 
assessing the risks of new 
substances
SAT 0 3.5 1 0 4.5 420 527.72 
 
326 866.56 747 394.29
Improving Europe’s 
capacity to monitor and 
evaluate policies
POL 0 4 1 0 5 434 595.88 
 
457 162.84 891 758.72
Scientific coordination, 
research and content 
support
SDI + IBS + 
POL
1 4.5 0 0 5.5 585 629.98 549 849.79 1 135 479.77
Total 4 26.7 8 1 39.7 3 553 661.08 3 670 588.89 7 224 249.97
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(2) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(3) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA 
mission/task/WP, as their immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion 
of the human resources assigned for the implementation of these activities.
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B. Cooperation and collaboration with key partners (transversal operations) 
WP objectives and 
activities
Main 
actors for 
implemen-
tation
Allocated human resources (fte/
year)(1)
Allocated budget resources — Non assigned 
appropriations (€)
O TA CA SNE Total 
HR
For direct cost of 
operations (2)
For indirect cost 
of operations (3)
Total budget
Cooperation with key 
partners: EU bodies, civil 
society and international 
organisations
DIR 0 0.5 0 0 0.5 114 471.80 93 298.50 207 770.30
SDI 0 1 0 0 1 132 390.78 111 765.06 244 155.84
Cooperation with key 
partners: candidate 
and potential candidate 
countries and European 
Neighbourhood Policy 
countries and other non-EU 
countries
RTX 0.3 2.3 0 0 2.6 199 889.75 242 576.17 442 465.92
Total 0.3 3.8 0 0 4.1 446 752.32 447 639.74 894 392.06
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(2) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(3) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA 
mission/task/WP, as their immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in 
proportion of the human resources assigned for the implementation of these activities.
C. Supporting the achievement of results (transversal operations) 
WP objectives and 
activities
Main 
actors for 
implemen-
tation
Allocated human resources (fte/
year)(1)
Allocated budget resources — Non assigned 
appropriations (€)
O TA CA SNE Total 
HR
For direct cost of 
operations (2)
For indirect cost 
of operations (3)
Total budget
Communicating the 
EMCDDA’s findings 
to external audiences 
(including translation)
COM 1 9 2 0 12 1 540 834.03 1 167 509.32 2 708 343.35
Governance, management 
and networks 
Governing 
bodies + 
DIR + IBS
3 5.3 2 0 10.3 986 547.19 870 732.45 1 857 279.64
RTX + 
NFPs’ co-
financed 
activities
0.7 2.2 1 0 3.9 3 043 177.72 328 410.72 3 371 588.44
Total 4.7 16.5 5 0 26.2 5 570 558.94 2 366 652.48 7 937 211.42
Grand Total for Operations (A+B+C) 9 47 13 1 70 9 570 972.34 6 484 881.10 16 055 853.44
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(2) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(3) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA 
mission/task/WP, as their immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion 
of the human resources assigned for the implementation of these activities.
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D. Support to operations under A, B and C above (overheads)
WP objectives and 
activities
Main 
actors for 
implemen-
tation
Allocated human resources (fte/
year)(1)
Allocated budget resources for direct cost of 
supporting activities to be distributed to operations(3) 
(see above) — Non assigned appropriations (€)O TA CA SNE Total 
HR
Administration supporting 
core business
ADM 3 13 7 0 23 3 124 051.76
Information and 
communication technology 
ICT 0 8 2 0 10 1 134 957.75
Total 3 21 9 0 33 4 259 009.52
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(3) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA 
mission/task/WP, as their immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion 
of the human resources assigned for the implementation of these activities.
E. Special projects
(Funded by supplementary appropriations from EU budget on top of the EU regular annual subsidy to the 
EMCDDA)
WP objectives and 
activities
Main 
actors for 
implemen-
tation
Allocated human resources (fte/
year)(1)
Allocated budget resources — Assigned appropriations 
(€)
O TA CA SNE Total 
HR
Preparation of IPA 
Beneficiaries Countries for 
their participation in the 
EMCDDA (IPA 4 project – 
2nd year)
RTX 0 0 2 0 2 350 000
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
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Beneficiaries for the 2013 EMCDDA grant 
agreement (8)
Unless there would be a reorganisation within 
the national public administration of one of the 
beneficiaries (i.e. EU national focal points), the 
potential beneficiaries for 2013 are the following:
AUSTRIA: Gesundheit Österreich GmbH (Austrian 
Health Institute); Stubenring 6; 1010 Wien.
BELGIUM: Wetenschappelijk Instituut 
Volksgezondheid / Institut Scientifique de Santé 
Publique (Scientific Institute of Public Health) — 
Patrimoine (IPH - Patrimoine); Rue Juliette Wytsman 
14; 1050 Brussels.
BULGARIA: National Centre for Addictions (NCA 
BG); Pirotska str. 117; 1303 Sofia.
CROATIA (from July 2013 onwards): Vlada Republike 
Hrvatske — Ured za suzbijanje zlouporabe droga 
(Government of the Republic of Croatia — Office for 
Combating Narcotic Drugs Abuse); Preobraženska 
4/II; HR - 10 000 Zagreb.
CYPRUS: Cyprus National Monitoring Centre for 
Drugs and Drug Addiction — EKTEPN; Antidrugs 
Council; Magnolia Center — Offices 11-12; 
Strovolos Avenue 32; 2018 Nicosia.
CZECH REPUBLIC: Úřad vlády České republiky 
(Secretariat of the National Drug Commission — 
Office of the Government of the Czech Republic), 
Nabřeží Edvarda Beneše 4; 118 01 Praha 1 - Malá 
Strana.
DENMARK: Danish Health and Medicines Authority; 
Axel Heides Gade 1; DK- 2300, Copenhagen S. 
Sundhedsstyrelsen (National Board of Health); 
Islands Brygge 67; 2300 Copenhagen S.
ESTONIA: Tervise Arengu Instituut (National Institute 
for Health Development — NIHD); Hiiu 42; 11619 
Tallinn.
FINLAND: Terveyden Ja Hyvinvoinnin Laitos 
(National Institute for Health and Welfare - THL), PO 
Box 30 - Mannerheimintie 166; 00271 Helsinki.
FRANCE: Observatoire Français des Drogues et des 
Toxicomanies (French Monitoring Centre for Drugs 
and Drug Addiction), Avenue du Stade de France 3; 
93218 Saint Denis La Plaine Cedex.
GERMANY: Institut für Therapieforschung (Institute 
for Therapy Research); Parzivalstrasse 25; 80804 
Munich.
GREECE: University Mental Health Research Institute 
— Greek Reitox Focal Point; Soranou tou Efesiou 2; 
Papagou; 115 27 Athens.
HUNGARY: Országos Epidemiológiai Központ 
(National Center for Epidemiology); Gyáli út 2-6; 
1097 Budapest.
IRELAND: Health Research Board (HRB) — Drugs 
Misuse Research Division; Lower Baggot Street 73; 
Dublin 2.
ITALY: Presidenza del Consiglio dei Ministri — 
Dipartimento Politiche Antidroga (Presidency of 
the Council of Ministers - Department for Antidrug 
Policies); Via Po 16/A; 00198 Roma.
LATVIA: Slimību profilakses un kontroles centra 
(Centre for Disease Prevention and Control of Latvia); 
Duntes Street 22; LV-1005 Riga.
LITHUANIA: Narkotikų, Tabako ir Alkoholio Kontrolés 
Departhamentas (Drug, Tobacco and Alcohol Control 
Department); Šv. Stepono 27; 01312 Vilnius.
LUXEMBOURG: Centre de Recherche Public — Santé 
(CRP-Santé); Rue Dicks 18; 1417 Luxembourg.
MALTA: Ministry for Social Policy; Republic Street 
310; Palazzo Ferreria; 2000 Valletta.
NETHERLANDS: Stichting Trimbos Instituut; Da 
Costakade 45; 3521 VS Utrecht.
POLAND: Krajowe Biuro Do Spraw Przeciwdzialania 
Narkomanii (National Bureau for Drugs Prevention); 
ul. Dereniowa 52-54; 02-776 Warsaw.
PORTUGAL: SICAD — Serviço de Intervenção nos 
Comportamentos Aditivos e nas Dependências; 
Avenida da República n° 61 - 7°; 1050- 89 Lisboa.
(8) Based on the decision of the EMCDDA Management Board of December 2007, the maximum amount of the grant receivable by the 
EU national focal points is indexed annually by 2%, in order to maintain the real value of the grant. Unless this decision is revised by the 
Board, the maximum EMCDDA contribution for each EU national focal point in the 2013 grant would be EUR 107 341.
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ROMANIA: Agenţia Natională Antidrog (National 
Anti-drug Agency); Unirii Boulevard 37; Bl. A4; 3rd 
district; 030823 Bucharest. 
SLOVAKIA: Ministerstvo zdravotníctva Slovenskej 
republiky (Ministry of Health of the Slovak Republic); 
Limbová 2, P.O.Box 52, 837 52 Bratislava 37.
SLOVENIA: Inštitut za Varovanje Zdravja Republike 
Slovenije (Institute of Public Health of the Republic of 
Slovenia); Trubarjeva 2; 1000 Ljubljana.
SPAIN: Delegación del Gobierno para el Plan 
Nacional sobre Drogas (Government Delegation for 
the National Plan on Drugs); Calle Recoletos 22; 
28001 Madrid.
SWEDEN: Statens Folkhälsoinstitut (National Institute 
of Public Health); SE 831 40 Östersund.
UNITED KINGDOM: Department of Health; Waterloo 
Road; Wellington House 133-155; London SE1 
8UG.
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Annex IV: Template of the 2013 Reitox grant agreement
The current grant agreement template is available under the following link:
www.emcdda.europa.eu/about/partners/reitox-network 
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List of abbreviations and acronyms
ABB Activity-based budgeting EU European Union
ABM Activity-based management EUFAS European Federation of Addiction Societies
BCB Business continuity plan  EUSPR European Society for Prevention Research
CADAP The Central Asia Drug Action Programme EWS Early warning system
CEPOL European Police College EQUS EU framework for minimum quality 
standards and benchmarks in drug demand 
reduction
CICAD Inter-American Drug Abuse Control 
Commission
GARP Global AIDS Response Progress
CoE / PG Council of Europe / Pompidou Group GPS General population survey
COPOLAD Cooperation Programme between Latin 
America and the European Union on Drugs 
Policies
HDG Horizontal Drugs Group
COSI Standing Committee on Internal Security of 
the European Union
HR Human Resources
CUP Cross unit project IAS Internal Audit Service
DRD Drug-related deaths ICARA International Confederation of Alcohol, 
Tobacco and other Drugs Research 
Association
DRID Drug-related infectious diseases IPA Instrument for Pre-Accession Assistance
EC European Commission ITN Initial training network
ECDC European Centre for Disease Prevention 
and Control
JHA Justice and Home Affairs group, European 
Commission
EDND European database on new drugs KI Key indicator
EDDRA European drug demand reduction action NFP National focal point
EIB Evaluation instruments bank NPAS New psychoactive substance
ELDD European legal database on drugs OAP Operational action plan
EMA European Medicines Agency PCC Potential candidate countries
EMDAS European Master in Drug and Alcohol 
Studies
PDU Problem drug use
EMQ European Model Questionnaire PhV Pharmacovigilance
EMS Environmental management system QSAR Quantitative structure-activity relationships
ENFSI European Network of Forensic Science 
Institutes
TDI Treatment demand indicator
UNAIDS Joint United Nations Programme 
on HIV/AIDS
ENP European neighbourhood policy UNODC United Nations Office on Drugs and Crime
ERANID European Research Area Network on Illicit 
Drugs
WCO World Customs Organization
ESPAD European School Survey Project on Alcohol 
and other Drugs
WHO World Health Organization
European Monitoring Centre for Drugs and Drug Addiction
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information on 
drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Agency’s publications are a prime source of information for a wide range 
of audiences including policymakers and their advisers, professionals and 
researchers working in the field of drugs, and, more broadly, the media and 
general public.
The EMCDDA’s annual work programme sets out the agency’s objectives 
and expected results to be implemented according to the three-year work 
programme and strategy.
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